

(19)



(11)

EP 2 225 274 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
15.02.2017 Bulletin 2017/07

(51) Int Cl.:
C07K 16/18 (2006.01) G01N 33/53 (2006.01)
G01N 33/68 (2006.01)

(21) Application number: **08860515.9**

(86) International application number:
PCT/US2008/086674

(22) Date of filing: **12.12.2008**

(87) International publication number:
WO 2009/076632 (18.06.2009 Gazette 2009/25)

(54) **COMPOSITIONS AND METHODS FOR EARLY PREGNANCY DIAGNOSIS**

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR FRÜHEN SCHWANGERSCHAFTSDIAGNOSE

COMPOSITIONS ET PROCÉDÉS POUR UN DIAGNOSTIC PRÉCOCE DE GROSSESSE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

- **GREEN, Jonathan**
Columbia,MO 65203 (US)

(30) Priority: **13.12.2007 US 13603 P**

(74) Representative: **dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB**
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln (DE)

(43) Date of publication of application:
08.09.2010 Bulletin 2010/36

(73) Proprietors:

- **Monsanto Technology, LLC**
St. Louis, MO 63167 (US)
- **The Curators Of The University Of Missouri**
Columbia, MO 65211-2015 (US)

(56) References cited:
US-A1- 2005 100 975 US-A1- 2007 166 773

(72) Inventors:

- **MATHIALAGAN, Nagappan**
St. Louis,MO 63167 (US)
- **ROBERTS, R., Michael**
Columbia,MO 65201 (US)
- **MCGRATH, Michael, F.**
St. Louis,MO 63167 (US)

- **GREEN J A ET AL: "The establishment of an ELISA for the detection of pregnancy-associated glycoproteins (PAGs) in the serum of pregnant cows and heifers" THERIOGENOLOGY, LOS ALTOS, CA, US, vol. 63, no. 5, 15 March 2005 (2005-03-15), pages 1481-1503, XP004752332 ISSN: 0093-691X**

EP 2 225 274 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

BACKGROUND OF THE INVENTION

I. Field of the Invention

[0001] The present invention relates generally to the fields of veterinary medicine, reproductive biology and diagnostics. More specifically, the present invention relates to methods and compositions for detecting early stage pregnancy in a bovine animal.

II. Related Art

[0002] Pregnancy diagnosis allows for sound reproductive management in the dairy and beef industry. In general, artificial insemination is successful less than 50% of the time and the producer must either rely on overt signs of return to estrus (that are easily missed) or delay rebreeding until pregnancy failure is confirmed by one of the methods described above. Such delays are extremely costly and constitute a major economic loss to the industry.

[0003] An accurate pregnancy test for cattle which can be performed early and which has low false positives has long been sought. Several pregnancy tests are available, including a milk progesterone assay (Oltenucu *et al.*, 1990; Markusfeld *et al.*, 1990), estrone sulfate analysis (Holdsworth *et al.*, 1982; Warnick *et al.*, 1995), rectal palpation (Hatzidakis *et al.*, 1993), ultrasound (Beal *et al.*, 1992; Cameron and Malmo, 1993), and blood tests for pregnancy-specific antigens.

[0004] Each of these procedures has fallen short of expectations in terms of their practical, on-farm use. For example, measurements of milk or serum progesterone around day 18-22 yield unacceptably high rates of false positives (Oltenucu *et al.*, 1990; Markusfeld *et al.*, 1990). Rectal palpation can be used to detect pregnancy as early as day 35, but this procedure can lead to 5-10% or greater embryonic mortality (Oltenucu *et al.*, 1990; Hatzidakis *et al.*, 1993). Rectal palpation on day 50 causes less damage to the embryos, but has only marginal economic value because of its lateness (Oltenucu *et al.*, 1990). Ultrasonography has an advantage over rectal palpation in accuracy, particularly before day 45 (Beal *et al.*, 1992; Cameron and Malmo, 1993), but the instrument is expensive, its use requires considerable training, and there is a finite risk to the animal. A related procedure, Doppler sonography, is more accurate than rectal palpation (Cameron and Malmo, 1993), but again requires well trained personnel. The presence of estrone sulfate in urine or serum provides another test but is only useful after day 100 as concentrations rise (Holdsworth *et al.*, 1982; Warnick *et al.*, 1995).

[0005] The discovery of pregnancy-specific protein B (PSP-B) (Butler *et al.*, 1982) provided a new approach to pregnancy diagnosis since it could be detected in the blood of pregnant cows by the fourth week of pregnancy (Sasser *et al.*, 1986; Humblot *et al.*, 1988). Others have developed immunoassays that may be based on an identical or immunologically similar antigen (Zoli *et al.*, 1992a; Mialon *et al.*, 1993; Mialon *et al.*, 1994). In one case, the antigen (Mr ~67 kDa) was called bovine pregnancy-associated glycoprotein (boPAG; now boPAG-1) (Zoli *et al.*, 1992a); in the second, it was designated as pregnancy serum protein 60 (PSP60) (Mialon *et al.*, 1993; Mialon *et al.*, 1994). The immunoassays for PSP-B/boPAG1/PSP60 have certain disadvantages. First, positive diagnosis in the fourth week of pregnancy remains somewhat uncertain because antigen concentrations in blood are low and somewhat variable. Second, boPAG1 concentrations rise markedly at term (Sasser *et al.*, 1986; Zoli *et al.*, 1992a; Mialon *et al.*, 1993) and, due to the long circulating half-life of the molecule (Kiracofe *et al.*, 1993), the antigen can still be detected 80-100 day postpartum (Zoli *et al.*, 1992a; Mialon *et al.*, 1993; Mialon *et al.*, 1994; Kiracofe *et al.*, 1993), compromising pregnancy diagnosis in cows bred within the early postpartum period. Thus, the test can be carried out in dairy cows at day 30 only if artificial insemination ("AI") is performed at or after 70 day post-partum.

[0006] Pregnancy-associated glycoproteins (PAGs) are structurally related to the pepsins. They are thought to be restricted to the hooved (ungulate) mammals and characterized by being expressed specifically in the outer epithelial cell layer (chorion/trophectoderm) of the placenta (Green *et al.*, 2000; Hughes *et al.*, 2003; Xie *et al.*, 1997). At least some PAGs are catalytically inactive as proteinases, although each appears to possess a cleft capable of binding peptides (Guruprasad *et al.*, 1996). It is estimated that cattle, sheep, and most probably all ruminant Artiodactyla possess dozens of PAG genes. The PAGs are highly diverse in sequence, with regions of hypervariability confined largely to surface-exposed loops.

[0007] Bovine pregnancy-associated glycoproteins (boPAGs/PSPB/PSP60) were discovered in attempts to develop pregnancy tests for livestock (Butler *et al.*, 1982; Sasser *et al.*, 1986; Zoli *et al.*, 1991; Zoli *et al.*, 1992a). In each attempt, rabbits were injected with extracts of placental cotyledons, and antibodies not directed against placental antigens were removed by adsorption with tissue extracts from non-pregnant animals. The resulting antisera provided the basis of an accurate pregnancy test for cattle and sheep as early as one month post-insemination.

[0008] Even in initial studies (Butler *et al.*, 1982; Zoli *et al.*, 1991; Xie *et al.*, 1991; Xie *et al.*, 1994; Xie *et al.*, 1996), it was clear that the boPAGs were heterogeneous in molecular weight and charge, and as more isoforms have been

purified it has become evident that they differ in their amino terminal sequences (Atkinson *et al.*, 1993; Xie *et al.*, 1997a). Further library screening has revealed additional transcripts in ruminants (Xie *et al.*, 1994; Xie *et al.*, 1995; Xie *et al.*, 1997b) and the existence of PAGs in non-ruminant species such as the pig (Szafranska *et al.*, 1995). PAG-like proteins (also known as 'pepsinogen F' or 'pepsin F') have been described in the horse and cat (Green *et al.*, 1999; Guruprasad *et al.*, 1996). Among the bovine PAGs that have been described are boPAG2, boPAG4, boPAG5, boPAG6, boPAG7, boPAG9, boPAG7v; boPAG9v; boPAG15; boPAG16; boPAG17; boPAG18; boPAG19; boPAG20 and boPAG21 (U.S. Patent 6,869,770). Information regarding methods for diagnosing early pregnancy by assaying for such PAGs can be found, for example, in U.S. Patent 6,869,770 and U.S. Patent App. Pub. No. 20050100975.

[0009] Methods for detecting pregnancy in bovine animals based on the use of the antibodies which recognize a plurality of PAGs have been described (Green *et al.*, 2005).

[0010] Most of the available tests for detecting pregnancy in cattle are less accurate prior to day 30 following breeding. Further, for many of the existing tests, skilled personnel are required. Thus, there is the need for an accurate and sensitive pregnancy test in cattle that can be performed quickly and easily prior to day 30 following breeding.

SUMMARY OF THE INVENTION

[0011] Therefore, one aspect of the present invention provides a sensitive and accurate test for early pregnancy. The present invention provides an early pregnancy test for bovine animals in which a specific polypeptide that includes a domain that is highly specific for a PAG can be detected with a high degree of sensitivity and specificity prior to the end of the fourth week of pregnancy. The ability to diagnose pregnancy at such an early stage is particularly useful in the dairy industry where animals are usually confined for at least part of the day and where intensive management is practiced. In particular the invention provides a method for detecting pregnancy in a bovine animal comprising:

(a) contacting a sample obtained from a bovine animal with an antibody or antibody fragment, wherein the antibody or antibody fragment comprises

- a 2D9 antibody or fragment or variant thereof, or
- an antibody that bind specifically to the pregnancy-associated antigens (PAGs): PAG4, PAG6, PAG9, PAG16, PAG 17, PAG 19, PAG20 and PAG21, wherein the light chain domain is selected from: a polypeptide sequence with at least 97% sequence identity to SEQ ID NO:1 and a polypeptide sequence comprising SEQ ID NO:1, and the heavy chain domain is selected from: a polypeptide sequence with at least 92% sequence identity to SEQ ID NO:2 and a polypeptide sequence comprising SEQ ID NO:2; and

(b) detecting contacting of the antibody or antibody fragment with at least one pregnancy associated antigen (PAG) in the sample, wherein detection of the PAG indicates that the animal is pregnant.

[0012] A hybridoma cell line that produces 2D9 was deposited with the Patent Depository of the American Type Culture Collection (ATCC), Manassas, Va., 20110-2209 on Aug. 2, 2007 and assigned Patent Deposit No. PTA-8566 (Identification Reference MON-PAG-2D9). The deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. § 112.

[0013] In certain embodiments, the light chain domain has 98% or more sequence identity to SEQ ID NO:1, including 99% or more sequence identity to SEQ ID NO:1. In further embodiments, the light chain domain comprises SEQ ID NO:1. In some embodiments, the heavy chain domain has at least 93% sequence identity to SEQ ID NO:2, including at least 94%, 95%, 96%, 97%, 98%, and 99% or more sequence identity to SEQ ID NO:2. In some specific embodiments, the heavy chain domain comprises SEQ ID NO:2. In further embodiments, the heavy chain has greater than 95% sequence identity with SEQ ID NO:2. In more particular embodiments, the heavy chain has greater than 98% sequence identity with SEQ ID NO:2. In other embodiments, the heavy chain comprises SEQ ID NO:2.

[0014] In some other particular embodiments, the antibody comprises a light chain comprising SEQ ID NO:3 and a heavy chain comprising SEQ ID NO:4. In particular, the invention pertains to methods for detecting pregnancy in a bovine animal comprising: (a) contacting a sample obtained from a bovine animal with 2D9 monoclonal antibody, and (b) detecting contacting of the antibody with one or more of boPAG4, boPAG6, boPAG9, boPAG16, boPAG17, boPAG19, boPAG20 or boPAG21 in the sample, wherein detection of the PAG(s) indicates that the animal is pregnant. The method for detecting pregnancy, for example, can be performed on day 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more following artificial insemination.

[0015] A sample may be any sample known or suspected of containing a PAG. In specific embodiments, the sample is saliva, serum, plasma, blood, milk or urine. Any effective amount of sample can be obtained from the animal. For

example, the amount may be 5 μ l, 10 μ l, 15 μ l, 20 μ l, 25 μ l, 30 μ l, 40 μ l, 50 μ l, 60 μ l, 70 μ l, 80 μ l, 90 μ l, 100 μ l, 150 μ l, 200 μ l, 250 μ l, 300 μ l, 350 μ l, 400 μ l, 450 μ l, 500 μ l, 550 μ l, 600 μ l, 700 μ l, 800 μ l, 900 μ l, 1 ml, 1.5 ml, 2.0 ml, 2.5 ml, 3.0 ml, 3.5 ml, 4.0 ml, 4.5 ml, 5.0 ml, or more.

5 [0016] Any method of detecting contacting of the antibody or antibody fragment with a PAG that is known to those of ordinary skill in the art is contemplated by the methods of the present invention. For example, the method may comprise ELISA or Western blot. In particular embodiments, the PAG to be detected is boPAG2, boPAG4, boPAG5, boPAG6, boPAG7, boPAG9, boPAG7v, boPAG9v, boPAG15, boPAG16, boPAG17, boPAG18, boPAG19, boPAG20, or boPAG21. In specific embodiments, the PAG is boPAG6. In some embodiments of the present methods, more than one PAG in each sample is detected. When applied to species other than cattle, detection of other PAGs produced at the time the trophoblast (pre-placenta) begins either to attach or to implant into the uterine wall of the mother is possible. The "early" PAGs in these species may cross-react immunologically with the PAGs useful in detecting early pregnancy in cattle.

10 [0017] In particular embodiments, the ELISA is a sandwich ELISA comprising binding of a PAG to the antibody or antibody fragment fixed to a substrate and a second antibody preparation labeled with an enzyme. For example, the substrate to which the antibody or antibody fragment is fixed may be a tube, a well, a vial, a strip, a dipstick, or a biosensor. 15 The enzyme, for example, may be alkaline phosphatase or horseradish peroxidase or any enzyme tag.

[0018] The present invention also pertains to an isolated polypeptide comprising an antibody that bind specifically to the pregnancy-associated antigens (PAGs): PAG4, PAG6, PAG9, PAG16, PAG 17, PAG 19, PAG20 and PAG21, wherein the light chain domain is selected from: a polypeptide sequence with at least 97% sequence identity to SEQ ID NO:1 and a polypeptide sequence comprising SEQ ID NO:1, and the heavy chain domain is selected from: a polypeptide 20 sequence with at least 92% sequence identity to SEQ ID NO:2 and a polypeptide sequence comprising SEQ ID NO:2.

[0019] In particular embodiments, the domain comprises greater than 98% sequence identity to SEQ ID NO:1. In more particular embodiments, the domain comprises SEQ ID NO:1. There may be one or more additional amino acid residues attached to either the N-terminus or the C-terminus of the domain. In a particular embodiment, the polypeptide is SEQ ID NO:1. In some embodiments, the domain comprises greater than 95% sequence identity to SEQ ID NO:2. In more 25 particular embodiments, the domain comprises greater than 98% sequence identity to SEQ ID NO:2. In a further particular embodiment, the polypeptide is SEQ ID NO:2. In other embodiments, the polypeptide comprises SEQ ID NO:3. In further embodiments, the polypeptide comprises SEQ ID NO:4. The present invention also pertains to an isolated and purified polynucleotide that encodes an antibody that bind specifically to the pregnancy-associated antigens (PAGs): PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20 and PAG21, wherein the light chain domain is selected from: a polypeptide 30 sequence with at least 97% sequence identity to SEQ ID NO:1 and a polypeptide sequence comprising SEQ ID NO:1, and the heavy chain domain is selected from a polypeptide sequence with at least 92% sequence identity to SEQ ID NO:2 and a polypeptide sequence comprising SEQ ID NO:2. In some embodiments, the polynucleotide encodes a polypeptide having greater than 98% sequence identity to SEQ ID NO:1. In particular embodiments, polynucleotide encodes SEQ ID NO:1. In some embodiments, the light chain encoded by the polynucleotide is SEQ ID NO:3 and/or 35 the heavy chain encoded by the polynucleotide is SEQ ID NO:4. In some particular embodiments, the polynucleotide comprises SEQ ID NO:5, and/or SEQ ID NO:6. The present invention also generally pertains to a hybridoma cell that secretes monoclonal antibody 2D9.

[0020] The present invention also pertains to kits for detecting the presence of a PAG in a bovine animal, wherein the kit includes an antibody or antibody fragment that specifically binds to the pregnancy-associated antigens (PAGs): PAG4, 40 PAG6, PAG9, PAG16, PAG17, PAG19, PAG20, and PAG21, and comprises a light chain and a heavy chain as described above. In one embodiment, the antibody or antibody fragment is attached to a support. For example, the support may be a polystyrene plate, test tube, a strip, a dipstick, or a biosensor.

[0021] In some embodiments, the kit further includes a detectable label. For example, the detectable label may be a fluorescent tag attached to the antibody or antibody fragment. In other embodiments, the detectable label is a chemiluminescent tag. In further embodiments, the detectable label is an enzyme, such as alkaline phosphatase or horseradish peroxidase. The kit may further include a substrate for the enzyme. In further embodiments, the kit includes a buffer or diluent. The kit may also optionally include disposable pipettes. Other kit components, including reagent reservoirs and instructions are well known to those of skill in the art and also are contemplated for use in the kits described herein.

[0022] The present invention also generally pertains to methods for detecting pregnancy in a bovine animal comprising: 50 (a) contacting a sample obtained from the bovine animal with an antibody or antibody fragment provided by the invention; and (b) detecting a PAG in the sample by contacting it with the antibody or antibody fragment, wherein detection of one or more of boPAG4, boPAG6, boPAG9, boPAG16, boPAG17, boPAG19, boPAG20 or boPAG21, including all possible combinations thereof, indicates that the animal is pregnant.

[0023] Other objects, features and advantages of the present invention will become apparent from the following detailed description. 55

BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1. Nucleic acid sequence of 2D9 light chain (SEQ ID NO:5). The start codon of the processed form (N-terminal amino acid) and the stop codon are indicated in bold.

FIG. 2. Nucleic acid sequence of 2D9 heavy chain (SEQ ID NO:6). The start codon of the processed form (N-terminal amino acid) and the stop codon are indicated in bold.

FIG. 3A, 3B. FIG. 3A - Peptide sequences of boPAG6 (top panel) and peptide sequences (bottom panel) identified in LC-MS-MS analysis (SEQ ID NOs:7-18) showed that PAGs eluted from 2D9-coated magnetic beads after immunoprecipitation of PAG enriched preparation mainly correspond to boPAG6. In order to identify all 2D9-binding components, an immuno-affinity chromatography purification of PAG enriched preparation was performed. The immuno-affinity column purified material was subjected to LC-MS-MS analysis. This analysis revealed that boPAG6 is the major 2D9 binding PAG and boPAG-4, boPAG-9, boPAG-20 and boPAG21 are minor 2D9 binding PAGs. FIG. 3B - Denaturing gel electrophoresis (SDS-PAGE) and Western blot analysis of PAGs purified from 2D9-immuno affinity chromatography of tissue extract prepared from day 55 bovine placenta. Both Coomassie stained gel and Western blot analysis with PAG polyclonal antibodies showed three protein bands at 67 kDa, 55 kDa and 50 kDa as 2D9-binding PAGs. "Mz" = mass to charge ratio: peptide mass to charge of ionized peptide, minus water; "Charge" = ion charge state; "Mr(calc)" = peptide calculated molecular weight; "Start" = start amino acid of the protein that peptide aligns with; "End" = stop amino acid of the protein that peptide aligns with; "Score" = measure of peptide sequence confidence.

FIG. 4. Coomassie blue stained SDS-PAGE showing 2D9 binding PAGs purified by immuno-affinity chromatography of caruncle (endometrium) and cotyledon (placenta) tissue extracts. Protein bands 1 to 7 were cut and subjected to trypsin digestion followed by LC-MS-MS analysis (SEQ ID NOS:7-18).

FIG. 5. Log-logit transformation of PAG ELISA standard curve developed with 2D9-antibody coated ELISA plates and immuno-affinity purified PAGs as standards. The assay showed a linear response from 0.5 ng/ml to 50 ng/ml.

FIG. 6. The tables set forth show the accuracy of day 28 pregnancy diagnosis by using a lab-based ELISA compared to pregnancy diagnosis on day 28 ultrasound in two study sites, Wisconsin and California. Economics of a day 28 pregnancy test in dairy cow reproduction management was examined in this beta study. A lab-based PAG ELISA with polyclonal antibodies was used for pregnancy diagnosis. Wisconsin site used strictly synchronized breeding while California site used synchronized breeding plus breeding to heat. Approximately 1000 cows were used in the study per site. Blood samples were collected on day 28, shipped to lab for pregnancy testing. The results were returned to farms within 24hrs to enable breeding decisions. Pregnancy status was also determined by ultrasound at the time of blood collection on day 28.

FIG. 7. Analysis results of breeding parameters in Wisconsin site trial. This site used a strictly synchronized breeding program with a day 28 pregnancy test (early resynch group) or with day 45 palpation (control group, late resynch). Results show a significant reduction in days between insemination and days open in the early resynch group (day 28 pregnancy test) compared to late resynch group (control group).

FIG. 8. Analysis results of breeding parameters in California site trial. This site used synchronized breeding plus breeding to heat with (early resynch group) and without (late resynch group) day 28 pregnancy test. Results show a significant reduction in days between insemination, number of inseminations and days open compared to late resynch group.

FIG. 9. Color test basis. Results of PAG immunoassay developed with 2D9 monoclonal antibody as capture antibody and biotin-labeled rabbit polyclonal antibody as second antibody. Plasma test panel (20 open and 20 pregnant) samples collected at day 28 and day 55 of pregnancy showed a complete separation of open cows (blue) compared to pregnant cows (pink). The near zero PAG value obtained for open cows suggested that a PAG standard may not be needed for qualitative detection of immunoreactive PAG in the test plasma.

FIG. 10. Results of bovine pregnancy diagnosis performed with whole blood samples in the color test. The results are visually read. Tubes showing blue color reaction solution (tubes 1, 3, 6, 9, 10, 14 and 15) are a positive result for pregnancy status and tubes showing clear background (tubes 2, 4, 5, 7, 8, 11, 12, 13 and 16) are negative (non-pregnant) for pregnancy status. For reading in a spectrophotometer, equal volume (0.4 ml) of stop solution (1N HCl) may be added to each tube. Addition of stop solution will turn the color to yellow. Then, the optical densities (OD) of each sample can be measured in a spectrophotometer at 630 nm.

FIG. 11A, 11B. Results of color test performed with 2D9-coated plastic tubes. FIG. 11A - Day 28 plasma panel. FIG. 11B -Day 55 plasma panel. All open cow samples in the day 28 and day 55 test panels produced a color intensity of 0.2 OD or less while pregnant plasma samples produced color intensity as high as 1.0 OD unit. In this

assay, day 28 plasma samples showed a 100% sensitivity and 100% specificity when 0.2 OD color intensity was set as a cut-off. At the same color intensity cut-off, the day 55 plasma samples showed 95% sensitivity and 100% specificity in the plastic tube assay.

FIG. 12. Comparison of pregnancy testing of fresh plasma samples with PAG sandwich ELISA performed with polyclonal antibodies (Poly:Poly, top panel) and 2D9 monoclonal antibody and poly clonal antibody (Mono:Poly, bottom panel). Note a clear separation of open cow samples easily distinguished by using 0.2 OD cut-off color intensity. All pregnant cow samples had color intensity >0.2 OD units. The Mono:Poly assay had 100% sensitivity and 100% specificity in this experiment.

FIG. 13. Field testing of color test with blood samples. Fifty four blood samples collected from days 33-34 after breeding were tested and the color was visually read by 3 personnel. There was no disagreement observed in visual scoring of results among 3 individuals.

FIG. 14. Field testing results of color test compared to ultrasound results of 54 samples. The test identified all pregnant cows (100% sensitivity) with one false positive result compared to ultrasound results. There were 2 samples with inconclusive results in the color test later found to be 'open' cows. However, the color test identified 37 of 40 open cows (92.5% specificity) compared to ultrasound.

FIG. 15. PAG isoform protein sequence clusters generated by the Neighbors Phylogenetic Tree analysis package of PROTDIST (v. 3.5c), within BioEdit (v. 7.0.5.3; www.mbio.ncsu.edu/BioEdit/BioEdit.html; Hall, 1999).

FIG. 16. Direct alignment of PAG isoforms 1, 4, 6, 9, 16, 17, 19, 20, and 21. Protein sequences for PAG isoforms and variants are given in SEQ ID NOs:51-62, derived from UniProt accessions Q29432, 046492, 046494, A5PJW4, 046497, A4FV16, Q9TTV8, Q9TTV7, A7MBA4, Q9TTV5, Q9TTV4, and Q9TTV3.

FIG. 17. SDS-PAGE gel of purified PAGs batches (5 µg each) stained with Coomassie blue illustrating the three PAGs bands (top, middle, and bottom bands) between 50 and 75 kDa. 1) Protein standards (Bio-Rad Cat. # 161-0374); 2) d55 caruncle; 3) d55 cotyledon; 4) d55 caruncle and cotyledon combined; 5) d215 caruncle; 6) d215 cotyledon; 7) d215 caruncle and cotyledon combined; 8) Protein standards (Bio-Rad Cat. # 161-0374).

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0025] Despite the availability of several assays to detect pregnancy, there remains a need to provide improved assays for accurate and early detection of pregnancy, especially in cattle that are bred within two to three months postpartum or earlier. Certain embodiments of the present invention pertain to methods of determining pregnancy status of a cow by performing a color test to measure binding of a PAG in a sample obtained from the animal with a polypeptide, such as monoclonal antibody 2D9, an antibody which binds to PAGs indicative of bovine pregnancy. The color test can be performed early, such as 26 days following insemination. The color test can be used in any of a variety of formats, such as with test tubes or ELISA plates. In particular embodiments, the test utilizes a sandwich immunoassay principle that uses a second antibody. A color, such as a blue color, indicates a positive test, while tubes that are clear indicate a negative test. Embodiments of the present methods can be performed easily prior to 30 days following artificial insemination, and are highly sensitive and specific. Further, multiple samples can be easily and quickly analyzed concurrently, which further improves the value of the present methods.

[0026] Also provided are antibodies and antigen-binding fragments that bind specifically to the pregnancy-associated antigens (PAGs): PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20, and PAG21 that comprise certain novel PAG-binding polypeptides that can be applied in methods to detect pregnancy in a subject, and polynucleotides encoding the polypeptides set forth herein. The remaining disclosure describes various features of the invention and their implementation.

I. Polypeptides

[0027] Some embodiments of the invention set forth herein pertain to isolated polypeptides comprising an antibody that binds specifically to PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20 and PAG21 and which include a PAG binding domain having greater than 97% sequence identity to SEQ ID NO:1 and greater than 92% sequence identity to SEQ ID NO:2. In some embodiments, the PAG binding domain has greater than 97.1%, 97.3%, 97.5%, 97.7%, 97.9%, 98.1%, 98.3%, 98.5%, 98.7%, 98.9%, 99.1%, 99.3%, 99.5%, 99.7%, 99.9%, or 100% sequence identity to SEQ ID NO:1. In some embodiments, the PAG binding domain has greater than 92.2%, 92.6%, 93.0%, 93.4%, 93.8%, 94.2%, 94.6%, 95.0%, 95.4%, 95.8%, 96.2%, 96.6%, 97.0%, 97.4%, 97.8%, 98.2%, 98.6%, 99.0%, 99.4%, 99.8%, or 100% sequence identity to SEQ ID NO:2. A "polypeptide" as used herein refers to a consecutive amino acid segment of any length. In some embodiments of the present methods, the polypeptides employed therein are consecutive amino acid sequences having at least 97% sequence identity to SEQ ID NO:1 or at least 92% sequence identity to SEQ ID NO:2. One of ordinary skill in the art would understand how to generate such a polypeptide in view of the disclosure set forth herein using any of a number of experimental methods well-known to those of skill in the art.

[0028] The term "percent sequence identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including those described in: Computational Molecular Biology (1988); Biocomputing: Informatics and Genome Projects (1993); Computer Analysis of Sequence Data, Part I (1994); Sequence Analysis in Molecular Biology (1987); and Sequence Analysis Primer (1991). Preferred methods to determine identity are designed to give the best match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Sequence alignments and percent identity calculations may be performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, Wis.). Multiple alignment of the sequences may be performed using the Clustal method of alignment (Higgins and Sharp (1989) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method are KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

[0029] It is well understood by the skilled artisan that, inherent in the definition of a "polypeptide," is the concept that there is a limit to the number of changes that may be made within a defined portion of the molecule and still result in a molecule with an acceptable level of sequence identity or function, e.g., ability of bind to a PAG.

[0030] An amino acid sequence of any length is contemplated within the definition of polypeptide as set forth herein, so long as the polypeptide retains the recited sequence identity. The PAG binding domain of the polypeptides set forth herein may have additional amino acids at either the C-terminal or N-terminal end. For example, the polypeptide equivalent may include 4, 5, 6, 7, 8, 9, 10, 15, 20, 50, 75, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or more additional nucleic acids attached to either the C-terminal end or N-terminal end of the PAG binding domain.

[0031] Of course, a plurality of distinct polypeptides with different substitutions may easily be made and used in accordance with the invention.

[0032] The present invention may utilize polypeptides purified from a natural source or from recombinantly-produced material. Those of ordinary skill in the art would know how to produce these polypeptides from recombinantly-produced material. This material may use the 20 common amino acids in naturally synthesized proteins, or one or more modified or unusual amino acids. Generally, "purified" will refer to a polypeptide composition that has been subjected to fractionation to remove various other proteins, polypeptides, or peptides, and which composition substantially retains its activity. Purification may be substantial, in which the polypeptide is the predominant species, or to homogeneity, which purification level would permit accurate degradative sequencing.

[0033] Amino acid sequence mutants are encompassed by the present invention, and are included within the definition of "polypeptide." Amino acid sequence mutants of the polypeptide can be substitutional mutants or insertional mutants. Insertional mutants typically involve the addition of material at a non-terminal point in the peptide. This may include the insertion of a few residues; an immunoreactive epitope; or simply a single residue. The added material may be modified, such as by methylation and acetylation. Alternatively, additional residues may be added to the N-terminal or C-terminal ends of the peptide.

[0034] Amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge and size. An analysis of the size, shape and type of the amino acid side-chain substituents reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape. Therefore, based upon these considerations, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as biologically functional equivalents.

[0035] In making changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5). The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, 1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within +2 is preferred, those which are within +1 are particularly preferred, and those within +0.5 are even more particularly preferred.

[0036] It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent protein. As detailed in U.S.

[0037] Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 + 1); glutamate (+3.0 + 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 + 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

[0038] In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within + 2 is preferred, those which are within + 1 are particularly preferred, and those within + 0.5 are even more particularly preferred.

5 II. Polynucleotides

[0039] Various aspects of the present invention pertain to polynucleotides that encode a polypeptide that includes a light chain domain with at least 97% sequence identity to SEQ ID NO:1 and a heavy chain domain with at least 92% sequence identity to SEQ ID NO:2. Also disclosed are polynucleotides comprising a nucleic acid sequence that has greater than 98% sequence identity to SEQ ID NO:5 or greater than 95% sequence identity to SEQ ID NO:6. SEQ ID NO:5 refers to the nucleic acid sequence of the cDNA that encodes the light chain of 2D9, and SEQ ID NO:6 refers to the nucleic acid sequence of the cDNA that encodes the heavy chain of 2D9.

[0040] The polynucleotides may be obtained from natural sources or chemically synthesized using any method known to those of ordinary skill in the art. The present invention also encompasses chemically synthesized mutants of these sequences.

[0041] In certain embodiments, one may wish to employ constructs which include other elements, for example, those which include C-5 propyne pyrimidines. Oligonucleotides which contain C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity (Wagner *et al.*, 1993). In some embodiments, the polynucleotide encodes one or more additional amino acid segments that can bind to a PAG.

20 III. Antibodies and Antibody Fragments

[0042] Particular embodiments of the present invention involve antibodies or antibody fragments. The term "antibody" is used to refer to any antibody-like molecule that has an antigen binding region, and includes antibody fragments such as Fab', Fab, F(ab')₂, single domain antibodies (DABs), Fv and scFv (single chain Fv). The techniques for preparing and using various antibody-based constructs and fragments are well known in the art. Means for preparing and characterizing antibodies are also well known in the art (See, *e.g.*, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988).

[0043] "Mini-antibodies" or "minibodies" are also contemplated for use with the present invention. Minibodies are sFv polypeptide chains which include oligomerization domains at their C-termini, separated from the sFv by a hinge region. Pack *et al.* (1992). The oligomerization domain comprises self-associating alpha-helices, *e.g.*, leucine zippers, that can be further stabilized by additional disulfide bonds. The oligomerization domain is designed to be compatible with vectorial folding across a membrane, a process thought to facilitate *in vivo* folding of the polypeptide into a functional binding protein. Generally, minibodies are produced using recombinant methods well known in the art. See, *e.g.*, Pack *et al.* (1992); Cumber *et al.* (1992).

[0044] Antibody-like binding peptidomimetics (ABiPS) as described by Liu *et al.*, 2003, are peptides that act as pared-down antibodies and have certain advantages of longer serum half-life as well as less cumbersome synthesis methods.

[0045] Monoclonal antibodies (MAbs) are recognized to have certain advantages, *e.g.*, reproducibility and large-scale production, and their use is generally preferred. Monoclonal antibodies can be of human, murine, monkey, rat, hamster, rabbit and even chicken origin. Due to the ease of preparation and ready availability of reagents, murine monoclonal antibodies will often be preferred.

[0046] However, "humanized" antibodies are also contemplated, as are chimeric antibodies from mouse, rat, or other species, bearing human constant and/or variable region domains, bispecific antibodies, recombinant and engineered antibodies and fragments thereof. As used herein, the term "humanized" immunoglobulin refers to an immunoglobulin comprising a human framework region and one or more complementarity determining regions (CDRs) from a non-human (usually a mouse or rat) immunoglobulin. The non-human immunoglobulin providing the CDRs is called the "donor" and the human immunoglobulin providing the framework is called the "acceptor". A "humanized antibody" is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin.

[0047] The term "antibody" includes polyclonal antibodies, monoclonal antibodies (mAbs), chimeric antibodies, anti-idiotypic (anti-Id) antibodies to antibodies that can be labeled in soluble or bound form, as well as fragments, regions or derivatives thereof, provided by any known technique, such as enzymatic cleavage, peptide synthesis or recombinant techniques. The antibodies set forth herein are capable of binding to a PAG.

[0048] "Polyclonal antibodies" are defined herein to refer to heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen. These different antibodies may recognize several epitopes on the same antigen. A "monoclonal antibody" contains a substantially homogeneous population of antibodies specific to antigens, which population contains substantially similar epitope binding sites. MAbs may be obtained by methods known to those skilled in the art. See, *e.g.*, Kohler and Milstein, 1975; U.S. Pat. No. 4,376,110; Ausubel *et al.*, 1992; Harlow and Lane 1988; Colligan *et al.*, 1993. Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA,

IgD and any subclass thereof. A hybridoma producing a mAb of the present invention may be cultivated *in vitro*, *in situ* or *in vivo*. Production of high titers of mAbs *in vivo* or *in situ* makes this the presently preferred method of production.

[0049] "Chimeric antibodies" are molecules, different portions of which are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, which are primarily used to reduce immunogenicity in application and to increase yields in production. Chimeric antibodies and methods for their production are known in the art. Exemplary methods of production are described in Cabilly *et al.*, 1984; Boulianne *et al.*, 1984; and Neuberger *et al.*, 1985.

[0050] An "anti-idiotypic antibody" (anti-Id) is an antibody which recognizes unique determinants generally associated with the antigen-binding site of an antibody. An anti-Id antibody can be prepared by immunizing an animal of the same species and genetic type (*e.g.*, mouse strain) as the source of the mAb with the mAb to which an anti-Id is being prepared. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody by producing an antibody to these idiotypic determinants (the anti-Id antibody). An exemplary method of producing such antibodies is found in U.S. Pat. No. 4,699,880.

[0051] Antibodies of the present invention can include at least one heavy and at least one light chain that bind specifically to the pregnancy-associated antigens (PAGs): PAG4, PAG6, PAG9, PAG16, PAG 17, PAG 19, PAG20 and PAG21.

IV. Detection Methods and Assay Formats

[0052] Certain embodiments of the present invention pertain to methods of detecting pregnancy in a bovine animal that involves contacting a sample obtained from the bovine animal with an antibody provided herein and detecting at least one pregnancy associated antigen in the sample, wherein detection of the PAG indicates the animal is pregnant. Any method known to those of ordinary skill in the art can be used to detect antibody or antibody fragments bound to a PAG in the sample.

[0053] The present invention therefore provides for the use of antibodies in the immunologic detection of PAGs. Various useful immunodetection methods have been described in the scientific literature, such as, *e.g.*, Nakamura *et al.* (1987). Immunoassays, in their most simple and direct sense, are binding assays. Certain immunoassays are enzyme linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA). Immunohistochemical detection using tissue sections also is particularly useful. However, it will be readily appreciated that detection is not limited to such techniques, and Western blotting, dot blotting and FACS analyses also may be used in connection with the present invention.

[0054] In general, immunobinding methods include obtaining a sample suspected of containing a protein, peptide or antibody, and contacting the sample with an antibody or protein or peptide in accordance with the present invention, as the case may be, under conditions effective to allow the formation of immunocomplexes. Preferred samples, according to the present invention, are fluids, such as milk, urine, blood, serum or saliva.

[0055] In particular embodiments, the antibody is linked to a solid support, such as the inner wall of a tube or well, and the sample suspected of containing the PAG will be applied to the immobilized antibody.

[0056] Antibody-coated tube systems are described in U.S. Patent 3,646,346 and WO 98/16832. Presence of PAG-antibody complexes can then be detected under specific conditions. Optionally, such immune complexes can be quantified.

[0057] Contacting the chosen biological sample with the antibody under effective conditions and for a period of time sufficient to allow the formation of immune complexes (primary immune complexes) is generally a matter of simply adding the antibody composition to the sample and incubating the mixture for a period of time long enough for the antibodies to form immune complexes with, *i.e.*, to bind to, any PAG present in the sample. After this time, the sample-antibody composition will generally be washed to remove any non-specifically bound antibody species, allowing only those antibodies specifically bound within the primary immune complexes to be detected.

[0058] In general, the detection of immunocomplex formation is well known in the art and may be achieved through the application of numerous approaches. These methods are generally based upon the detection of a label or marker, such as any of those radioactive, fluorescent, biological and enzymatic tags. U.S. Patents concerning the use of such labels include 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241. Methods for the immunological determination of proteins and kits for carrying out the method can be found in U.S. Patent 5,721,105.

[0059] The method may involve the use of a secondary binding ligand such as a second antibody and/or a biotin/avidin ligand binding arrangement, as is known in the art. The secondary antibody employed in the detection may itself be linked to a detectable label, wherein one would then simply detect this label, thereby allowing the amount of the primary immune complexes in the composition to be determined. Methods for the detection of a biomolecule in a test sample using immunocapture, biotin/avidin amplification, and horseradish peroxidase color production can be found in U.S. Patent App. Pub. No. 2003/508381.

[0060] Usually, the primary immune complexes may be detected by means of a second binding ligand that has binding affinity for the PAG or the PAG-specific first antibody. In these cases, the second binding ligand may be linked to a detectable label. The second binding ligand is itself often an antibody, which may thus be termed a "secondary" antibody.

The primary immune complexes are contacted with the labeled, secondary binding ligand, or antibody, under conditions effective and for a period of time sufficient to allow the formation of secondary immune complexes. The secondary immune complexes are then generally washed to remove any non-specifically bound labeled secondary antibodies or ligands, and the remaining label in the secondary immune complexes is then detected.

5 **[0061]** Further methods include the detection of primary immune complexes by a two step approach. A second binding ligand, such as an antibody, that has binding affinity for the PAG or anti-PAG antibody is used to form secondary immune complexes, as described above. The second binding ligand contains an enzyme capable of processing a substrate to a detectable product and, hence, amplifying signal over time. After washing, the secondary immune complexes are contacted with substrate, permitting detection.

10 **[0062]** In one embodiment of the invention, enzyme-linked immunoassay (ELISA) may be used. See, e.g., Engvall, 1980; Engvall, 1976; Engvall, 1977; Gripenberg *et al.*, 1978; Makler *et al.*, 1981; Sarangadharan *et al.*, 1984. ELISA allows for substances to be passively adsorbed to solid supports such as plastic to enable facile handling under laboratory conditions. For a comprehensive treatise on ELISA the skilled artisan is referred to "ELISA; Theory and Practise" (Crowther, 1995).

15 **[0063]** The sensitivity of ELISA methods is dependent on the turnover of the enzyme used and the ease of detection of the product of the enzyme reaction. Enhancement of the sensitivity of these assay systems can be achieved by the use of fluorescent and radioactive substrates for the enzymes. Immunoassays encompassed by the present invention include, those described in U.S. Patent 4,367,110 (double monoclonal antibody sandwich assay) and U.S. Patent 4,452,901 (western blot). Other assays include immunoprecipitation of labeled ligands and immunocytochemistry, both
20 *in vitro* and *in vivo*.

[0064] In one embodiment, the invention comprises a "sandwich" ELISA, where anti-PAG antibodies of the present invention are immobilized onto a selected surface, such as a well in a polystyrene microtiter plate, a tube, or a dipstick. Then, a test composition suspected of containing PAGs, e.g., a clinical sample, is contacted with the surface. After binding and washing to remove non-specifically bound immunocomplexes, the bound antigen may be detected by a
25 second antibody to the PAG.

[0065] In another exemplary ELISA, polypeptides from the sample are immobilized onto a surface and then contacted with the anti-PAG antibodies. After binding and washing to remove non-specifically bound immune complexes, the bound antibody is detected. Where the initial antibodies are linked to a detectable label, the primary immune complexes may be detected directly. Alternatively, the immune complexes may be detected using a second antibody that has binding
30 affinity for the first antibody, with the second antibody being linked to a detectable label.

[0066] Another ELISA in which the PAGs are immobilized involves the use of antibody competition in the detection. In this ELISA, labeled antibodies are added to the wells, allowed to bind to the PAG, and detected by means of their label. The amount of PAG in a sample is determined by mixing the sample with the labeled antibodies before or during
35 incubation with coated wells. The presence of PAG in the sample acts to reduce the amount of antibody available for binding to the well, and thus reduces the ultimate signal.

[0067] Irrespective of the format employed, ELISAs have certain features in common, such as coating, incubating or binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. In coating a plate with either antigen or antibody, one will generally incubate the wells of the plate with a solution of the antigen or antibody, either overnight or for a specified period of hours. The wells of the plate will then be washed to remove
40 incompletely adsorbed material. Any remaining available surfaces of the wells are then "coated" with a nonspecific protein that is antigenically neutral with regard to the test antisera. These can include bovine serum albumin (BSA), casein, solutions of milk powder or other antigenically neutral proteins. The coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface.

45 **[0068]** "Under conditions effective to allow immune complex (antigen/antibody) formation" means that the conditions preferably include diluting the antigens and antibodies with solutions such as BSA, bovine gamma globulin (BGG), evaporated or powdered milk, and phosphate buffered saline (PBS)/TWEEN. These added agents also tend to assist in the reduction of nonspecific background.

[0069] The "suitable" conditions also mean that the incubation is at a temperature and for a period of time sufficient
50 to allow effective binding. Incubation steps are typically from about 1h to 2h to 4 h, at temperatures preferably on the order of 25°C to 27°C, or may be overnight at 4°C.

[0070] To provide a detecting means, the second or third antibody will have an associated label to allow detection. Often, this will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate. Thus, for example, one will desire to contact and incubate the first or second immune complex with a urease,
55 glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of further immunocomplex formation (e.g., incubation for 2 h at room temperature in a PBS-containing solution such as PBS-TWEEN). After incubation with the labeled antibody, and subsequent to washing to remove unbound material, the amount of label is quantified, e.g., by incubation with a chromogenic substrate

such as urea and bromocresol purple or 2,2'-azido-di-(3-ethyl-benzthiazoline-6-sulfonic acid [ABTS] and H₂O₂, in the case of peroxidase as the enzyme label. Quantitation is then achieved by measuring the degree of color generation, e.g., using a visible spectra spectrophotometer. A variant of ELISA is the enzyme-linked coagulation assay, or ELCA (U.S. Patent 4,668,621), which uses the coagulation cascade combined with the labeling enzyme RVV-XA as a universal detection system. The advantage of this system for the current invention, is that the coagulation reactions can be performed at physiological pH in the presence of a wide variety of buffers. It is therefore possible to retain the integrity of complex analytes.

[0071] Immunohistochemistry (IHC) may also be used according to the present invention in the identification of PAGs. This involves testing of both fresh-frozen and formalin-fixed, paraffin-embedded tissue blocks prepared from study by IHC. For example, each tissue block consists of 50 mg of residual "pulverized" placental tissue. The method of preparing tissue blocks from these particulate specimens has been successfully used in previous IHC studies of various prognostic factors, e.g., in breast, and is well known to those of skill in the art (Brown *et al.*, 1990; Abbondanzo *et al.*, 1990; Allred *et al.*, 1990).

[0072] Briefly, frozen-sections may be prepared by rehydrating 50 mg of frozen "pulverized" placental tissue at room temperature in phosphate buffered saline (PBS) in small plastic capsules; pelleting the particles by centrifugation; re-suspending them in a viscous embedding medium (OCT); inverting the capsule and pelleting again by centrifugation; snap-freezing in -70°C isopentane; cutting the plastic capsule and removing the frozen cylinder of tissue; securing the tissue cylinder on a cryostat microtome chuck; and cutting 25-50 serial sections containing an average of 500 remarkably intact placental cells.

[0073] Permanent-sections may be prepared by a similar method involving rehydration of the 50 mg sample in a plastic microfuge tube; pelleting; resuspending in 10% formalin for 4 h fixation; washing/pelleting; resuspending in warm 2.5% agar; pelleting; cooling in ice water to harden the agar; removing the tissue/agar block from the tube; infiltrating and embedding the block in paraffin; and cutting up to 50 serial permanent sections.

V. Purification of Proteins

[0074] Protein purification techniques are well known to those of skill in the art. These techniques involve, at one level, the crude fractionation of the cellular milieu to polypeptide and non-polypeptide fractions. Having separated the polypeptide from other proteins, the polypeptide of interest may be further purified using chromatographic and electrophoretic techniques to achieve partial or complete purification (or purification to homogeneity). Analytical methods particularly suited to the preparation of a pure peptide are ion-exchange chromatography, exclusion chromatography; polyacrylamide gel electrophoresis; isoelectric focusing. A particularly efficient method of purifying peptides is fast protein liquid chromatography or even HPLC.

[0075] The term "purified polypeptide, protein or peptide" as used herein, is intended to refer to a composition, isolatable from other components, wherein the protein or peptide is purified to any degree relative to its naturally-obtainable state. A purified protein or peptide therefore also refers to a protein or peptide, free from the environment in which it may naturally occur. Generally, "purified" will refer to a protein or peptide composition that has been subjected to fractionation to remove various other components, and which composition substantially retains its expressed biological activity. Where the term "substantially purified" is used, this designation will refer to a composition in which the protein or peptide forms the major component of the composition, such as constituting 50%, 60%, 70%, 80%, 90%, 95% or more of the proteins in the composition.

[0076] Various techniques suitable for use in protein purification will be well known to those of skill in the art. These include, for example, precipitation with ammonium sulphate, PEG and antibodies or by heat or acid pH denaturation of contaminating proteins, followed by centrifugation; chromatography steps such as ion exchange, gel filtration, reverse phase, hydroxylapatite and affinity chromatography; isoelectric focusing; gel electrophoresis; and combinations of such and other techniques. As is generally known in the art, it is believed that the order of conducting the various purification steps may be changed, or that certain steps may be omitted, and still result in a suitable method for the preparation of a substantially purified protein or peptide.

[0077] There is no general requirement that the polypeptide always be provided in its most purified state. Indeed, it is contemplated that less substantially purified products will have utility in certain embodiments. Partial purification may be accomplished by using fewer purification steps in combination, or by utilizing different forms of the same general purification scheme. For example, it is appreciated that a cation-exchange column chromatography performed utilizing an HPLC apparatus will generally result in a greater "-fold" purification than the same technique utilizing a low pressure chromatography system. Methods exhibiting a lower degree of relative purification may have advantages in total recovery of protein product, or in maintaining the activity of an expressed protein.

VI. Kits

[0078] In still further embodiments, the present invention provides kits for use with the immunodetection methods described above for the detection of PAGs, such as an immunodetection kit to diagnose pregnancy in a bovine. In specific embodiments, an antibody comprising a light chain domain with at least 97% sequence identity to SEQ ID NO:1 and a heavy chain domain with at least 92% sequence identity to SEQ ID NO:2 are included in the kit. The kit may include one or more container means. The container, for example, may be a vial, a tube, a flask, or a syringe.

[0079] In particular embodiments, the antibody is monoclonal antibody 2D9. In particular embodiments, the kit includes one or more tubes or wells of a microtiter plate with prebound antibody. Alternatively, the kit may include antibody prebound to a column matrix. The kit may allow for the assay of a single sample, or more than one sample. In some embodiments, the kit includes a plurality of microtiter plates or tubes coated with antibody which allow for immunodetection of numerous samples concurrently or consecutively.

[0080] The immunodetection reagents of the kit may take any one of a variety of forms, including those detectable labels that are associated with and/or linked to the given antibody. Detectable labels that are associated with and/or attached to a secondary binding ligand are also contemplated. Exemplary secondary ligands are those secondary antibodies that have binding affinity for the first antibody.

[0081] The kits may include a secondary antibody that has binding affinity for the first antibody. The second antibody may or may not be linked to a detectable label. The kit may further include a third antibody that has binding affinity for the second antibody, the third antibody being linked to a detectable label. As noted above, a number of exemplary labels are known in the art and/or all such labels may be employed in connection with the present invention.

[0082] The kits may optionally include a suitably aliquoted composition of a PAG to provide for a positive control. The components of the kits may be packaged either in aqueous media and/or in lyophilized form.

VII. Examples

[0083] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice.

Example 1

Identification of 2D9 binding PAGs

[0084] Studies were undertaken to identify the proteins binding to 2D9, to characterize and sequence the 2D9 antibody, and to map the binding sites of PAG to 2D9. In order to accomplish this, two approaches (described below) were undertaken.

Materials and Methods.

[0085] Immunoprecipitation of PAGs with 2D9-coated magnetic beads. Purified 2D9 was coupled to Tosyl-activated Dynal magnetic beads according to manufacturer's directions (Dynal). The antibody coated magnetic beads were incubated with 100 micrograms of PAG enriched preparation (obtained from day 55 placenta) for 30 min in 1x PBS and washed extensively with the same buffer. The bound proteins were eluted by using pH 3.0 acetic acid and subjected to gel and Western blot analysis. Western blot was developed with rabbit anti-PAG polyclonal antibodies. The immunoreactive protein bands were cut from SDS-PAGE and subjected to LC-MS-MS analysis after trypsin digestion (FIG. 3).

[0086] Immuno-affinity chromatography of tissue extracts prepared from caruncle (endometrium) and cotyledonary (placenta) tissues from day 55 of bovine pregnancy. Briefly, purified 2D9 (10 mg) was coupled to 1 gram of CNBr-activated sepharose according to manufacturer's directions (Sigma, St. Louis). The 2D9-affinity resin (approximately 5.0ml) was incubated 25 ml tissue extract at pH 7.0, overnight for binding. Next day, the resin was packed in a column and washed with 1xPBS to remove unbound materials and eluted with pH 3.0 acetic acid. The pH of the eluted material was neutralized with 1M Tris immediately after elution to pH 7.0. The eluted material was subjected gel and Western blot analysis. Western blot was developed with rabbit anti-PAG polyclonal antibodies. The protein bands 1 to 7 were cut from SDS-PAGE and subjected to LC-MS-MS analysis after trypsin digestion (FIG. 4). The identities of peptide sequences were determined by using BLAST analysis.

[0087] The binding affinity of PAG to 2D9 was determined by log-log transformation of ELISA data (FIG. 5) developed with 2D9-binding antigen as PAG standards (purified by immuno-affinity chromatography). The assay was performed with a series of PAG standards ranging from 0.05 ng/ml to 50 ng/ml (0.083 nM to 8.3 nM). The ELISA assay was repeated

EP 2 225 274 B1

8 times. The data was analyzed with SoftMax™ (Molecular Devices, Inc., Sunnyvale, CA).

Results

[0088] Immunoprecipitation of PAGs with 2D9-coupled magnetic beads. SDS-PAGE and Western blot analysis of magnetic bead eluted material showed a single protein band at 67kD. Peptide finger printing and LC-MS-MS analysis identified this protein band as boPAG6 (FIG. 3). However, this analysis did not reveal all PAGs binding to 2D9 since the analysis used 100 micrograms of PAG enriched preparation for immunoprecipitation experiment. This material was isolated by pepstatin-affinity chromatography of placental tissue extract at pH 5.0, followed by elution at pH 9.5. This preparation was also called 'acidic-PAGs', an enriched preparation of early PAG antigens. In order to identify all PAGs binding to 2D9, an immuno-affinity chromatography with tissue extracts were performed (see below).

[0089] Analysis of PAGs purified from tissue extracts with 2D9-immuno-affinity chromatography. Coomassie blue staining of immuno-affinity column eluted material showed 3 protein bands with molecular weights 67 kD, 55 kD and 50 kD. All three protein bands were also found to be immuno-reactive in Western blot analysis with rabbit anti-PAG antibodies. Based on these results, all protein bands were cut after SDS-PAGE (FIG. 4) and subjected to peptide finger printing and LC-MS-MS. The identities of resulting peptide sequences were determined by BLAST analysis. Table 1 shows a summary of the peptide sequence results and their identification as PAGs corresponding to boPAG-4, boPAG-6, boPAG-9, boPAG-20 and boPAG21 sequences by BLAST analysis. For meaning of parameters in Table 1, see description of FIG. 3.

Table 1. Summary of peptide sequence results

Protein Band No.: Present in Bands 3, 5, 6 & 7						
Bos Taurus (gi28603710) Pregnancy-associated glycoprotein 4						
Mz	Charge	Mr(calc)	Start	End	Score	Peptide sequence
494.7897	2	969.5647	323	331	97.72%	VPGQAYILK (SEQ ID NO:19)
523.7799	2	1027.5127	362	369	99.00%	LYFSVFDR (SEQ ID NO:20)
544.7657	2	1069.5193	127	136	98.95%	TFSITYGSGR (SEQ ID NO:21)
608.8262	2	1197.6216	232	241	94.10%	GELNWIPLMK (SEQ ID NO:22)
671.695	3	1994.0513	195	212	99.00%	LKNEGAISEPVFAFYLSK (SEQ ID NO:23)
820.4574	3	2440.2678	172	194	87.95%	FDGVLGLSYTNISPSGAIPFYK (SEQ ID NO:24)
Protein Band No.: Present in Bands 1, 2, 4 & 5						
Bos Taurus (gi28603714) Pregnancy-associated glycoprotein 6						
Mz	Charge	Mr(calc)	Start	End	Score	Peptide sequence
886.4235	2	1752.8722	196	211	88.08%	NEGAISEPVFAFYLSK (SEQ ID NO:25)
881.9394	2	1743.8865	147	162	95.46%	IGDLVSTDQPFGLCLK (SEQ ID NO:26)
809.7131	3	2408.1736	231	250	91.77%	GELNWWPLIQVDWVHMDR (SEQ ID NO:27)
671.6718	3	1994.0513	194	211	97.94%	LKNEGAISEPVFAFYLSK (SEQ ID NO:28)
615.3026	2	1210.6022	183	193	98.74%	TFSGAFPIFDK (SEQ ID NO:29)
592.9321	3	1757.8154	212	227	99.00%	DKQEGSVVMFGGVDHR (SEQ ID NO:30)
511.9066	3	1514.6936	214	227	90.49%	QEGSVVMFGGVDHR (SEQ ID NO:31)
467.2242	2	914.4286	362	368	91.26%	YFSVFDR (SEQ ID NO:32)

EP 2 225 274 B1

(continued)

Protein Band No.: Present in Bands 2 & 5						
Bos Taurus (gi28603720) Pregnancy-associated glycoprotein 9						
Mz	Charge	Mr(calc)	Start	End	Score	Peptide sequence
467.2146	2	914.4286	362	368	99.00%	YFSVFDR (SEQ ID NO:33)
521.2636	2	1022.5185	138	146	99.00%	GFLAYDTVR (SEQ ID NO:34)
653.9534	3	1940.8727	214	230	96.15%	QEGSVVMFGGVDHQYYK (SEQ ID NO:35)
654.80054	2	1289.5962	126	137	97.70%	TFTITYGSGSMK (SEQ ID NO:36)
660.8375	2	1301.6768	350	360	94.72%	ETWILGDAFLR (SEQ ID NO:37)
734.6413	3	2183.0105	212	230	87.19%	NKQEGSVVMFGGVDHQYYK (SEQ ID NO:38)
739.9147	2	1459.8439	307	319	99.00%	YLPSITFIINGIK (SEQ ID NO:39)
817.7423	3	2432.2222	147	169	99.00%	IGDLVSTDQPFGLSVVEYGLEGR (SEQ ID NO:40)
875.3999	3	2605.2012	256	280	83.62%	TVIACSDGCEALVHTGTSHIEGPGR (SEQ ID NO:41)
Protein Band No.: Present in Bands 1 & 4						
Bos Taurus (gi28603736) Pregnancy-associated glycoprotein 20						
Mz	Charge	Mr(calc)	Start	End	Score	Peptide sequence
671.6718	3	1994.0513	195	212	97.94%	LKNEGAISEPVFAFYLSK (SEQ ID NO:42)
758.8157	2	1497.7511	215	228	80.98%	QKGSVVMFGGVDHR (SEQ ID NO:43)
886.4235	2	1752.8722	197	212	88.08%	NEGAISEPVFAFYLSK (SEQ ID NO:44)
Protein Band No.: Present in Bands 3, 5 & 7						
Bos Taurus (gi28603738) Pregnancy-associated glycoprotein 21						
Mz	Charge	Mr(calc)	Start	End	Score	Peptide sequence
516.7575	2	1013.497	362	369	99.00%	VYFSVFDR (SEQ ID NO:45)
544.7657	2	1069.5193	127	136	98.95%	TFSITYGSGR (SEQ ID NO:46)
694.3238	3	2061.9712	258	277	98.47%	VVACSDGCEAVVDTGTSLIK (SEQ ID NO:47)
753.6964	3	2240.1	148	168	99.00%	IGDLVSTDQPFGLSVSEYGFK (SEQ ID NO:48)
892.1082	3	2655.2744	171	194	99.00%	AYDGILGLNYPDESFEAIPFDK (SEQ ID NO:49)
915.4483	2	1810.8889	346	361	81.37%	FSSSTETWLLGDAFLR (SEQ ID NO:50)

[0090] This analysis showed that each of the 3 protein bands have more than one PAGs (Table 1). The 67kD band contained peptides corresponding to boPAG6 and boPAG20. The 55 kD protein band contained peptides belonging to boPAG6 and boPAG9. The 50 kD protein band corresponded to boPAG4 and boPAG21 with boPAG9 as minor component. These results show that 2D9 monoclonal antibody binds to boPAG4, boPAG6, boPAG9, boPAG20 and boPAG21. This monoclonal antibody binds to epitopes common to all 5 PAGs. Sequence comparison showed a high degree of sequence identity among these PAGs.

[0091] The PAG ELISA results (FIG. 5) obtained by using 2D9-binding PAGs as standards was used for calculating Kd value by using SoftMax™. The Kd value of 2D9 was determined to be 0.9 nM (FIG. 5). Thus, 2D9 is a high affinity monoclonal antibody for PAGs. These results show that 2D9, a PAG monoclonal antibody, binds to boPAG4, boPAG6, boPAG9, boPAG20 and boPAG21 from a day 55 placental tissue extracts. The identities of peptide sequences obtained by LC-MS-MS corresponded with a previously characterized sequences of these 5 PAGs (boPAG4, boPAG6, boPAG9, boPAG20 and boPAG21).

Example 2**Protein and mRNA Sequencing**

5 **[0092]** Protein Sequencing of Purified 2D9. The sequencing of 2D9 was performed in order to identify PAG-antigen binding sequences of 2D9. The sequencing of 2D9 was accomplished by protein and DNA sequencing methods. First, heavy and light chains of 2D9 antibody were separated by denaturing gel electrophoresis. The gel bands were excised and subjected to trypsin and chymotrypsin enzyme digestions, separately. The resulting peptides were separated and
10 sequenced by LC-MS-MS (Liquid Chromatography-Mass Spectrometry-Mass Spectrometry) method. The peptides with >90% confidence score in the mass and sequence analysis were selected. The resulting peptide sequences were used to assemble ~80% of light chain sequence and ~50% of heavy chain sequence.

[0093] Sequencing of 2D9 Heavy and Light Chain mRNA. In a second approach, mRNA corresponding to 2D9 heavy and light chains were sequenced by using reverse transcription-polymerase chain reaction (RT-PCR) technique with total RNA prepared from 2D9 PAG hybridoma cells.

15 **[0094]** Briefly, PAG monoclonal antibody producing hybridoma cells were grown in serum-free tissue culture medium to produce 1×10^6 cells. The cells were centrifuged and the resulting cell pellet was snap frozen in liquid nitrogen. The cell pellet was stored at -80°C until use. The first strand complementary DNA (cDNA) was produced by using Cell-to-cDNA kit II purchased from Ambion, Inc., Austin, TX. The RNA in the hybridoma cells was reverse transcribed to produce cDNA without a separate RNA extraction step. The resulting cDNA template was used for amplifying light and heavy
20 chains by using polymerase chain reaction (PCR) with a set of primers designed for amplifying all subclasses of mouse heavy and light chains (Chardes *et al.*, 1999). The resulting PCR product was sequenced. The sequence data was assembled with DNA STAR™ software package. The entire study was repeated to ensure sequence accuracy. Second repetition of PCR amplification and sequencing included additional primers to increase the coverage.

25 **[0095]** Sequence analysis showed that 2D9 heavy chain was derived from mouse IgG1 gamma subclass and the light chain was derived from kappa type. Heavy chain consisted of 448 amino acid residues and the light chain consisted of 219 amino acid residues. The amino acid sequence of 2D9 light chain is set forth as SEQ ID NO:3. The amino acid sequence of 2D9 heavy chain is set forth as SEQ ID NO:4. The nucleic acid sequence of 2D9 light chain is set forth as SEQ ID NO:5 (FIG. 1). The nucleic acid sequence of 2D9 heavy chain is set forth as SEQ ID NO:6 (FIG. 2).

Example 3**Feasibility Studies of an Immunoassay-Based Pregnancy Test in Cattle**

35 **[0096]** A large-scale study was conducted to evaluate the economics of day 28 early pregnancy testing in the reproductive management of dairy cows. Study animals were located at two different sites, one in California and one in Wisconsin. 1,050 animals were assigned per site. Initial breeding was followed by either performance of an immunoassay based pregnancy test as described below, or by standard palpation. Samples were shipped to the laboratory overnight. The study used a sandwich ELISA optimized with rabbit anti-PAG polyclonal antibodies. The PAG ELISA used a cut off was 1.7 ng/ml, based on a trial study. Blood samples were collected on day 28 and shipped to laboratory for pregnancy
40 testing. Pregnancy diagnosis was accomplished by PAG ELISA and a report of results was generated, and made available within 24 hours to farm personnel. Breeding decisions were made based on pregnancy diagnosis results from PAG test for early resynch group. Breeding decisions for the late resynch group (control) were made based on palpation at days 35 to 45. Results from the two sites are shown in FIGS. 6-8.

45 **[0097]** FIG. 6 shows the accuracy of a lab-based pregnancy diagnosis with PAG ELISA compared to ultrasound based pregnancy diagnosis. FIG. 6 show the accuracy of day 28 pregnancy diagnosis by using a lab-based ELISA compared to pregnancy diagnosis on day 28 ultrasound in two study sites, Wisconsin and California. Economics of a day 28 pregnancy test in dairy cow reproduction management was examined in this beta study. A lab-based PAG ELISA with polyclonal antibodies was used for pregnancy diagnosis. Wisconsin site used strictly synchronized breeding while California site used synchronized breeding plus breeding to heat. Approximately 1000 cows were used in the study per site.
50 Blood samples were collected on day 28, shipped to lab for pregnancy testing. The results were returned to farms within 24 hrs to enable breeding decisions. Pregnancy status was also determined by ultrasound at the time of blood collection on day 28.

[0098] FIG. 7 and FIG. 8 show the results of breeding parameters used for determining economics of early pregnancy detection in the reproductive management of dairy cows in two different breeding schemes. The results clearly show
55 that there is a significant reduction in the days open by 10 to 15 days in the early resynch group compared to controls. In addition, a reduction in the days between inseminations was observed in both sites.

[0099] These results show that early pregnancy testing with PAG ELISA after 27-30 days of insemination allowed earlier breeding compared to palpation. Early pregnancy testing significantly reduced 'days open' in re-breeding of cows.

In addition, early pregnancy testing significantly reduced days between insemination. Breeding to heat strategy with early pregnancy testing was shown to reduce the number of inseminations per conception.

Example 4

On-Farm Test Concepts: Bovine Pregnancy Test (Strips)

[0100] A further study was conducted to evaluate the feasibility of use of 2D9 in developing an 'on-farm' pregnancy test with test strips. The test strips used lateral flow technology, which is the same technology used in home pregnancy tests. Lateral flow test strips have colloidal gold conjugated antibody at the sample application end and a capture antibody placed as a test line at the middle of the strip. If test antigen (PAG) is present in the sample, then gold conjugated antibody will bind to antigen and the resulting complex migrates towards test line. At the test line, the capture antibody (also raised against PAG) will bind to this complex and concentrate at the line. When sufficient complexes are retained at the test line as an antibody sandwich, a visible purple line will appear due to colloidal gold labeled antibody bound to test antigen. Lateral flow strips with more than 40 combinations of antibodies (including 2D9 as capture antibody) were produced and tested. None of the lateral flow strip combinations tested produced acceptable sensitivity and specificity. As a result, other rapid diagnostic test formats were evaluated for developing an 'on-farm' test. Among the formats evaluated, plastic tubes with internal fins showed promising results. Because of this, the tube format was selected for further optimization as a color test.

Example 5

On-Farm Test Concepts: Bovine Pregnancy Test (Multi-well Plates)

[0101] In a further study, plasma samples collected from day 28 of confirmed pregnant cows was used to determine the sensitivity and specificity of the color test. Color intensity was determined by transferring the sample solution to a multi-well plate coated with 2D9. The plate was read in a plate reader (SpectraMax, Molecular Devices, Inc., CA). The plasma panel consisted of 20 pregnant and 20 open (non-pregnant) samples. Each sample was assayed in duplicate. Based on the optical density of color intensities obtained from the 40 samples, by using a 0.2 OD unit cut-off as a background color, the test showed 100% sensitivity and 100% specificity (FIG. 9).

Example 6

On-Farm Test Concepts: Bovine Color Pregnancy Test (Plastic Tubes)

[0102] Materials and Methods. Following protocol describes the optimized procedure for pregnancy testing with 2D9-coated plastic tubes. The test can be performed with whole blood sample collected with K3EDTA blood collection tubes or with plasma samples.

[0103] Materials. Tubes with internal ribs (#214-2131-010) were purchased from Evergreen Scientific Company, Los Angeles, California. PAG monoclonal antibody, 2D9 and rabbit polyclonal antibodies were purified by Protein G affinity chromatography. Biotin-labeling of rabbit polyclonal antibodies was accomplished by using Roche biotin-labeling kit (#1-418-165, Roche Applied Science, Indianapolis, Indiana) according to manufacturer's directions. Streptavidin-PolyHRP20® (#RDI-PHRP20-SA) was purchased from Research Diagnostics, Inc, Concord, MA. Sure Blue Reserve® (#53-00-03) was procured from KPL, Inc, Gaithersburg, MD. SuperBlock with TWEEN20® (# 37516) was acquired from Pierce Biotech, Rockford, IL. Purified 2D9 monoclonal antibody in Phosphate Buffered Saline (pH7.4) with known concentration; Coating buffer: 0.1M Na₂CO₃, pH 9.3; Wash buffer: 1xPBS with 0.05% Tween20; Dilution buffer: 10% SuperBlock™ in wash buffer.

[0104] Biotin-labeling of polyclonal antibodies. Purified rabbit polyclonal antibody (1 mg) was used for biotin labeling according to recommended procedure by the kit manufacturer (Roche). Briefly, 7.6 μl of activated biotin reagent in DMSO was added to 1 mg of antibody in 1.0 ml of PBS solution in a 1.5 ml tube. The tube was placed on a rotary shaker with 45 rpm setting for 2 hours at room temperature. After this step, the contents were transferred to a dialysis slide-A-lyzer™ (Pierce Biotech, #63380) and dialyzed against 1xPBS at 4°C for 16 hours with 2 buffer changes. Biotin labeled IgG was recovered from the Slide-A-lyzer and stored as 1:100 diluted stock with 1% BSA in PBS. This solution was diluted to 1:2000 with dilution buffer for pregnancy testing prior to use.

[0105] Antibody coating of tubes. Purified monoclonal antibody, 2D9 was diluted in 0.1M sodium carbonate buffer (pH 9.3) to a concentration of 1.25 μg/ml for coating tubes. The tubes were coated with 0.5 μg of antibody in 0.4 ml of sodium carbonate buffer for 16 to 18 hours at 4°C for coating. For incubation, the tubes were placed inside of a plastic container with an air-tight lid closed tightly plus a moist paper towel for humidity and held at 4°C. After incubation, the antibody

EP 2 225 274 B1

solution was removed and the tubes were washed twice with wash buffer. The tubes were then blocked with 0.4 ml of superbloc-TWEEN20 for 1 hr at 37°C. After incubation, the superbloc was removed and the tubes were dried by placing them in a dry chamber for 2 hours at room temperature. Following this step, the tubes were sealed and stored at 4°C in a humidity-free plastic container until use. The coated tubes were useable for 6 months with minimal loss in test performance

[0106] Sample collection. Cows were bred to a synchronized heat using an OvSynch synchronization protocol. Approximately 200 cows were used for each synchronized breeding. A total of 815 cows were bred by artificial insemination (AI) and the day of AI was day 0. Blood sample from 800 cows were collected in tubes with anticoagulant K3EDTA (BD #366643) from cows on days 26 and 28 and shipped to laboratory in ice by overnight shipment. The blood samples were used directly in the color test upon receipt. The cows were checked for pregnancy status by ultrasound on day -29 and re-confirmed by rectal palpation on day -60. Pregnancy diagnosis data of 797 cows were available at the end of the study was used for analysis of test accuracy.

Color Test procedure:

[0107] The blood samples were mixed by inversion up to 10 times to facilitate easy sample transfer. Four hundred microliters (0.4 ml) of blood was transferred to each tube and the tubes were incubated in a 37°C water bath for 15 min. After this incubation, the blood sample was aspirated and the tubes were filled with wash buffer (1xPBS with 0.05% Tween20). The wash buffer was aspirated and the tubes were washed an additional 2 times with wash buffer. After the third wash, 0.4 ml of 1:2000 diluted biotin-labeled anti-PAG polyclonal antibody in dilution buffer (10% SuperblockT20™ in wash buffer) was added to each tube and incubated for 15 min at 37°C in a water bath. Following the incubation, the tubes were aspirated and washed twice with wash buffer. Next, 0.4 ml of streptavidin-PolyHRP20 (1:30,000) in dilution buffer was added to each tube and incubated for 15 min at 37°C in a water bath. After the third incubation, the content of each tube was aspirated and the tube was washed twice with wash buffer. Next, 0.4 ml of the HRP substrate, SureBlueReserve™, was added and incubated at room temperature for 15 min. Following incubation, a deep blue color was observed in tubes that received samples from pregnant cows (FIG. 10). Tubes that received samples from non-pregnant animals remained clear (FIG. 10). The color can be visually read to infer pregnancy status. However, to quantitate color in the laboratory, an equal volume of (0.4 ml) of stop solution (1N HCl) was added to each tube turning the blue color yellow. An aliquot (0.2 ml) from each sample was then transferred to ELISA plate and optical density was recorded at 430 nm. OD values above or equal to 0.2 were considered 'pregnant' and values below were considered 'open'. The color intensity cut off of 0.2 OD was previously established with plasma test panel samples was used for pregnancy diagnosis.

[0108] The following is a brief summary of the steps for the tube test procedure:

1. Add 400 µl of sample, 15 min at 37°C
2. Wash 3X for blood, 2X for plasma
3. Add 400 µl of Biotin label, 15 min at 37°C
4. Wash 2X
5. Add 400 µl of Poly-HRP20, 15 min at 37°C
6. Wash 2X
7. Add 400 µl of SureBlue Reserve™
8. Read - 5 min-15 min (Blue = pregnant; clear=open (nonpregnant))

Definitions of test analysis parameters:

[0109]

Sensitivity: Ability of the blood test to identify pregnant cows as pregnant

Specificity: Ability of blood test to identify open (non-pregnant) cows as open cow

[0110] Advantages of the color test: The test supplies include a purple cap blood tube (3.0 ml with K₂EDTA) for blood collection, pre-coated tubes, reagents, squirt bottle, and transfer pipettes. A 37°C incubator/waterback/block is required. Unlike plate ELISA, this test does not require centrifuge for separating plasma since whole blood can be used directly in the test. The test also does not require equipments like plate shaker, equipment for washing (plate washer) or reading (plate reader). The washing can be accomplished with squirt bottles and transfer pipettes are used for the removal of wash buffer solution between washes. The color can be visually read. However, in the laboratory, at the end of the color test (after step 8), 0.4 ml of stop solution 1N HCl is added to all tubes and an aliquot (0.2 ml) is transferred

to an ELISA plate and color intensity is recorded in a plate reader. The total assay time is approximately 2 hours compared to conventional plate ELISA (4 hours). This color assay can be optionally multiplexed, such as with 96-well, 48-well or 24-well plates.

[0111] Results. Results of the color test with day 28 plasma test panel (20 open and 20 pregnant samples) are shown in FIG. 11A, and results of the test with day 55 plasma test panel (20 open and 20 pregnant samples) are shown in FIG. 11B. All open samples have color intensity value ≤ 0.2 OD while pregnant samples showed color intensity > 0.2 OD. By using this cut-off value, both test panels (FIG. 11A and 11B) showed $> 95\%$ sensitivity and specificity. A set fresh plasma samples were also tested in this system and shown to provide a clear separation of open cows and pregnant cows (FIG. 12).

Example 7

On-Farm Test Concepts: Bovine Color Pregnancy Test (Plastic Tubes)

[0112] The test was performed 'on-farm' as described by using a 37°C water bath and no additional equipment. In this field test, 58 blood samples were tested. Color test was performed with 0.4 ml of blood samples (FIG. 13) and pregnancy confirmation was accomplished by ultrasound (FIG. 14). The color was read by 3 personnel and there was no disagreement in visual scoring of test results. The color test was able to identify all 14 pregnant cows. All 3 individuals scored 'inconclusive' with 2 samples due to blue background and the samples were found to be 'open'. This field testing showed 100% sensitivity and 92.5% specificity (37/40) compared to ultrasound.

Example 8

Sandwich Immunoassay-Based Color Pregnancy Test (Plastic Tubes)

[0113] Materials and Methods. A sandwich immunoassay based test was developed by using PAG monoclonal antibody, 2D9 as a capture antibody and biotin-labeled rabbit polyclonal antibody as second antibody. The PAG monoclonal antibody is coated inside of a transparent plastic tube or well and serves as a trap. The tubes used were internally ribbed tubes to increase surface area for antibody coating (Evergreen Scientific, Los Angeles, CA). The complex is detected with streptavidin-HRP (horseradish peroxidase)/HRP substrate system. Streptavidin Poly-HRP20 was obtained from Research Diagnostics Inc., Concord, MA, and Horseradish Peroxidase was obtained from KPL, Inc., Gaithersburg, MD. Detection of the complex is indicated by a color (blue or yellow) in the tube or well, indicating the presence of PAGs in the sample. Information regarding the general establishment of an ELISA for the detection of PAGs in the serum of pregnant cows and heifers can be found in Green *et al.*, 2005. The assay standard was 0.5 ng to 6.0 ng. The test takes about 4 hours to complete.

[0114] The test can be performed with simple laboratory supplies on a farm or comparable site. In this example, a 37°C incubator and pipettes are the only components required beside reagent supplies. The color test concept can be combined with Ovsynch, Resynch and Timed Artificial Insemination (TAI) as part of a reproductive management tool for cattle. The test concept can also be extended to other analytes such as progesterone and other pregnancy antigens to increase the accuracy of diagnosis or to advance detection of pregnancy prior to day 26. Multiplexing can be performed by using, for example, 96-well or 48-well trays or by using multiple tubes.

Table 2. Assay reagents, supplies and supplier information.

Item	Assay Reagent/Supplies	Purpose	Supplier Information
1	2D9 Monoclonal antibody	Coating antibody	
2	Rabbit polyclonal antibody	Biotin-labeled second antibody	
3	Streptavidin-Poly Horseradish Peroxidase (HRP) 20	Signal amplification	Research Diagnostics Inc., Concord, MA
4	Sure Blue Reserve™	Color substrate for HRP	KPL Inc, Gaithersburg, MD
5	Super Block	Used in blocking buffer, wash buffer and dilution buffer.	Pierce Biotechnology Inc., Rockford, IL
6	Internally ribbed tubes, 12X75 mm tube, polystyrene with 6 bottom ribs.	Tube used for the test	Evergreen Scientific, Los Angeles, CA

EP 2 225 274 B1

(continued)

Item	Assay Reagent/Supplies	Purpose	Supplier Information
7	Phosphate Buffered Saline	Buffer medium for coating, blocking, washing & dilution of biotin-IgG, HRP reagents.	Roche
8	Biotin labeling kit (5 reactions) and Dialysis kit, Slide-A-Lyzer™	Preparation of biotin-labeled IgG	Roche
9	Tween 20	Detergent used in buffer for coating, blocking, washing & dilution of biotin-IgG, HRP reagents at 0.05% conc.	Sigma Aldrich, St. Louis, MO.
10	Sodium Carbonate	Antibody coating buffer	Sigma Aldrich, St. Louis, MO.

[0115] Results. Pregnancy testing of 797 blood samples collected from day 26 and day 28 animals were evaluated for sensitivity and specificity by comparing to day 29 ultrasound and day 60 rectal palpation results. Plasma samples were obtained. A cut-off of 0.2 OD units for pregnancy diagnosis. Table 3 shows the accuracy of blood test compared to day 29 ultrasound based pregnancy diagnosis and day 60 rectal palpation.

Table 3. Analysis of blood test accuracy compared to day 29 ultrasound (US) and day 60 rectal palpation.

Day of blood test	Day 26		Day 28	
Number of cows tested	357	357	797	797
Pregnancy check	Day 29 US	Day 60 Palpation	Day 29 US	Day 60 Palpation
Sensitivity	97.4%	97.5%	99.3%	99.3%
Specificity	90.1%	91.2%	90.9%	91.2%

[0116] These results show that a bovine pregnancy test developed with PAG monoclonal antibody, 2D9, provides commercially acceptable accuracy with low false-negative results. This antibody can be applied in developing rapid test formats for detecting pregnancy status of cows as early as day 26 after breeding with high sensitivity and specificity. Further analysis showed that the test accuracy can be improved to 99% sensitivity and 94% specificity by adjusting cut-off value to 0.35 OD units.

Example 9

Isolation of a Sub-Group of Early PAG Proteins Suitable for Developing a Bovine Pregnancy Test

[0117] Tissue collection. Fetal cotyledon tissue was collected from early pregnant bovines 50 to 60 days after insemination. Fifty to sixty days of pregnancy is a preferred period in gestation because the sub-group of early PAG proteins represents a high percentage of the total PAG proteins at or about this stage of gestation. But while the percentage of the desirable, early PAG protein is high at or about 50 to 60 days after insemination, total protein and the amount of available tissue is small. At or about 61 to 250 days after insemination, total PAG protein and the quantity of fetal cotyledon and caruncle tissue is much greater.

[0118] Methods which may be undertaken to identify the proteins binding to 2D9 and to map the binding sites of PAG to 2D9. There are four approaches which may be taken in order to identify the proteins binding to 2D9, to characterize and sequence the 2D9 antibody, and to map the binding sites of PAG to 2D9. The following study was conducted:

1. Immunoprecipitation of PAGs (obtained from day 55 placenta) with 2D9-coated magnetic beads. Purified 2D9 were coupled to Tosyl-activated Dynal magnetic beads according to manufacturer's directions (Dynal). The antibody coated magnetic beads were incubated with 100 micrograms of PAG enriched preparation for 30 min in 1x PBS and washed extensively with the same buffer. The bound proteins were eluted by using pH 3.0 acetic acid

EP 2 225 274 B1

and subjected gel and Western blot analysis. Western blot was developed with rabbit anti-PAG polyclonal antibodies. The immuno-reactive protein bands were cut from SDS-PAGE and subjected to LC-MS-MS analysis after trypsin digestion.

5 [0119] The following method is an alternative immunoprecipitation method which may be performed:

2. **Immunoprecipitation of PAGs (obtained from day 61 to 250 placenta) with 2D9-coated magnetic beads.** Purified 2D9 may be coupled to Tosyl-activated Dynal magnetic beads according to manufacturer's directions (Dynal). The antibody coated magnetic beads may be incubated with 100 micrograms of PAG preparation for 30 min in 1x PBS and washed extensively with the same buffer. The bound proteins may be eluted by using pH 3.0 acetic acid and subjected gel and Western blot analysis. Western blot may be developed with rabbit anti-PAG polyclonal antibodies. The immuno-reactive protein bands may then be cut from SDS-PAGE and subjected to LC-MS-MS analysis after trypsin digestion. A highly purified preparation of the sub-group of early PAG proteins (specifically PAGs 4, 6, 9, 20 and 21) may be purified using this procedure.

10
15 [0120] The following study was conducted:

3. **Immuno-affinity chromatography of tissue extracts prepared from caruncle (endometrium) and cotyledonary (placenta) tissues from day 55 of bovine pregnancy.** Briefly, purified 2D9 (10 mg) was coupled to 1 gram of CNBr-activated sepharose according to manufacturer's directions (Sigma, St. Louis). The 2D9-affinity resin (approximately 5.0ml) was incubated with 25 ml tissue extract at pH 7.0, overnight for binding. Next day, the resin was packed in a column and washed with 1xPBS to remove unbound materials and eluted with pH 3.0 acetic acid. The pH of the eluted material was neutralized with 1M Tris immediately after elution to pH 7.0. The eluted material was subjected gel and Western blot analysis. Western blot was developed with rabbit anti-PAG polyclonal antibodies. The protein bands 1 to 7 were cut from SDS-PAGE and subjected to LC-MS-MS analysis after trypsin digestion. The identities of peptide sequences were determined by using BLAST analysis.

20
25 [0121] The following is an alternative chromatographic procedure which may be performed:

4. **Immuno-affinity chromatography of tissue extracts prepared from caruncle (endometrium) and cotyledonary (placenta) tissues from day 61 to 250 of bovine pregnancy.** Briefly, purified 2D9 (10 mg) may be coupled to 1 gram of CNBr-activated sepharose according to manufacturer's directions (Sigma, St. Louis). The 2D9-affinity resin (approximately 5.0ml) may be incubated with 25 ml tissue extract at pH 7.0, overnight for binding. Next day, the resin may be packed in a column and washed with 1x PBS to remove unbound materials and eluted with pH 3.0 acetic acid. The pH of the eluted material may be neutralized with 1M Tris immediately after elution to pH 7.0. The eluted material may be subjected gel and Western blot analysis. Western blot may be developed with rabbit anti-PAG polyclonal antibodies. The protein bands 1 to 7 may be cut from SDS-PAGE and subjected to LC-MS-MS analysis after trypsin digestion. The identities of peptide sequences may then be determined by using BLAST analysis. A highly purified preparation of the sub-group of early PAG proteins (specifically PAGs 4, 6, 9, 20 and 21) may be purified using this procedure.

Example 10

Identification of additional 2D9 binding PAGs

45 [0122] The MAb 2D9 was found to recognize five PAG isoforms (4, 6, 9, 20, and 21) as summarized in Example 1. These isoforms were identified by LC/MS/MS peptide sequencing of purified PAGs samples obtained from placental tissues harvested 55 days post breeding. MAb 2D9 was further utilized for purification and identification of PAGs by coupling the antibody to a CNBr-activated resin to create an immuno-affinity column. PAGs present in a purified sample may be bound (recognized) by 2D9. In a similar manner, PAGs present in bovine whole blood or plasma samples in the PAGs ELISA may be bound by 2D9 and elicit a positive ELISA response, indicating pregnancy. Elution of purified PAGs during the immuno-purification procedure was modified by adjusting pH from 3.0 to 2.5 with immediate neutralization to pH 7.0 during eluent collection. Visualization of purified PAGs by SDS-PAGE with purified samples was performed essentially as described above (e.g. Example 1). Similar banding patterns, with three major bands between 50 and 75 kDa were seen.

50
55 [0123] In addition to placental tissues harvested from cows 55 days post breeding, PAGs were also purified from placental tissues harvested from cows 215 days post breeding. Certain members of the PAGs protein family (isoforms) are expressed earlier in gestation than others. The set of PAGs expressed earlier in gestation are commonly referred

EP 2 225 274 B1

to as early PAGs and the set of PAGs expressed later in gestation are commonly referred to as late PAGs. Placental tissues from 55 days post breeding are representative of a gestation stage expressing early PAGs, while placental tissues from 215 days post breeding are representative of a gestation stage including late PAGs expression. Visualization of purified PAGs by SDS-PAGE from day 55 and day 215 placental tissues shows the same three bands between 50 and 75 kDa for both, however the proportion (intensity) of the higher molecular weight band is greater from day 215 placental tissues.

[0124] Peptides from PAGs samples from both day 55 and day 215 placental tissues were purified with a 2D9 immunoaffinity column and analyzed by LC/MS/MS peptide sequencing to identify the PAG isoform(s) present in the samples. Peptide sequences were compared with PAG isoform sequences obtained from UniProt database (www.uniprot.org) as listed in Table 4. Table 5 shows a summary of the peptide sequence results and their identification as PAGs corresponding to boPAG-16, boPAG-17, and boPAG-19 sequences by BLAST analysis. "Lanes" and "bands" (bottom, middle) referred to in Table 5 are shown in FIG. 17. A summary of the PAG isoforms characterized in the purified PAGs samples is shown in Table 6.

Table 4. PAG isoforms with UniProt accession numbers (SEQ ID NOs:51-62).

PAG isoform	Accession number
1	Q29432
4	046492
6	046494, A5PJW4
9	046497, A4FV16
16	Q9TTV8
17	Q9TTV7, A7MBA4
19	Q9TTV5
20	Q9TTV4
21	Q9TTV3

Table 5. Summary of peptide sequence results (including SEQ ID NOs:63-74). "MH+" = peptide mass to charge plus water; "Charge" = ion charge state; "P(pep)" = probability of peptide sequence; "Start" = start amino acid of protein that peptide aligns with; "End" = stop amino acid of protein that peptide aligns with.

Protein Band No.: Present in Bands Lane 2 (bottom), Lane 3 (middle), Lane 6 (middle), Lane 7 (middle and bottom)					
Bos Taurus (gi75074836) Pregnancy-associated glycoprotein 16					
MH+	Charge	Start	End	P(pep)	Peptide sequence
1389.65796	2	215	229	2.54E-05	REGSVVMFGGVDHRY (SEQ ID NO:63)
1046.53052	2	361	370	6.28E-04	RLYFSVFDRG (SEQ ID NO:64)
1770.90613	2	197	212	7.51E-06	NQGAISDPIFAFYLSK (SEQ ID NO:65)
Protein Band No.: Present in Bands Lane 2 (bottom), Lane 3 (bottom), Lane 4 (bottom), Lane 5 (bottom), Lane 6 (bottom), Lane 7 (bottom)					
Bos Taurus (gi75074835) Pregnancy-associated glycoprotein 17					
MH+	Charge	Start	End	P(pep)	Peptide sequence
1389.65796	2	215	229	2.54E-05	REGSWMFGGVDHRY (SEQ ID NO:66)
1035.58337	2	138	148	1.69E-05	KGLLVYDTVRI (SEQ ID NO:67)

EP 2 225 274 B1

(continued)

Protein Band No.: Present in Bands Lane 2 (bottom), Lane 3 (bottom), Lane 4 (bottom), Lane 5 (bottom), Lane 6 (bottom), Lane 7 (bottom)					
Bos Taurus (gi75074835) Pregnancy-associated glycoprotein 17					
MH+	Charge	Start	End	P(pep)	Peptide sequence
1046.53052	2	361	370	6.28E-04	RLYFSVFDRG (SEQ ID NO:68)
1771.89014	2	196	213	7.53E-07	KNEGAISEPVFAFYLSKD (SEQ ID NO:69)
Protein Band No.: Present in Bands Lane 3 (middle), Lane 4 (middle), Lane 5 (middle), Lane 6 (middle)					
Bos Taurus (gi75051662) Pregnancy-associated glycoprotein 19					
MH+	Charge	Start	End	P(pep)	Peptide sequence
1760.83850	3	212	229	1.00E-06	KDKQEGSVVMFGGVDHRY (SEQ ID NO:70)
1088.53711	2	126	137	4.36E-06	KTFSITYGSGRI (SEQ ID NO:71)
2243.06616	3	213	231	1.32E-03	DKQEGSVVMFGGVDHRYR (SEQ ID NO:72)
1046-53052	2	361	370	9.55E-04	RLYFSVFDRG (SEQ ID NO:73)
1770.90613	2	196	213	6.03E-09	KNQGAISEPVFAFYLSKD (SEQ ID NO:74)

Table 6. PAG isoforms characterized in Day 55 and Day 215 placental tissues.

Day 55 Tissue Type	PAG Isoforms	Day 215 Tissue Type	PAG Isoforms
caruncle	4, 6, 9, 16, 17, 21	caruncle	4, 6, 9, 17, 19, 21
cotyledon	4, 6, 9, 16, 17, 19, 21	cotyledon	4, 6, 9, 16, 17, 19, 21
caruncle/cotyledon	4, 6, 9, 17, 19	caruncle/cotyledon	4, 6, 9, 16, 17, 21

[0125] Polypeptide sequences shown in Table 4 were aligned using PROTDIST v. 3.5c, e.g. from the PHYLIP package (Felsenstein, 1989). The NeighborPhylogenetic Tree analysis package of PROTDIST was used on the aligned sequences to generate the tree shown in FIG. 15. Alignments of the PAGs are shown in FIG. 16. This analysis of PAG isoforms 1, 4, 6, 9, 16, 17, 19, 20, and 21 was performed to visualize the relatedness of the isoforms based on their regions of similarity and difference. According to the analysis, PAGs 4, 6, 9, 16, 17, 19, 20, and 21 cluster together, apart from PAG1.

REFERENCES

[0126]

U.S. Patents 3,646,346; 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,275,149; 4,277,437; 4,366,241; 4,367,110; 4,376,110; 4,452,901; 4,668,621; 4,699,880; 5,721,105; and 6,869,770.
 U.S. Patent Publns. 2003/508381 and 20050100975.
 Abbondanzo et al., Breast Cancer Res. Treat., 16:182(151), 1990.
 Allred et al., Breast Cancer Res. Treat., 16:182(149), 1990.
 Atkinson et al., J. Biol. Chem., 268(35):26679-26685, 1993.
 Ausubel et al., In: Current Protocols in Molecular Biology, John, Wiley & Sons, Inc, NY, 1994; 1992.
 Beal et al., J. Anim. Sci., 70:924-929, 1992.
 Biocomputing: Informatics and Genome Projects, Smith (Ed.), Academic Press, NY, 1993.
 Boulianne et al., Nature, 312:643-646, 1984.

- Brown et al., *Breast Cancer Res. Treat.*, 16: 192(#191), 1990.
 Butler et al., *Biol. Reprod.*, 26:925-933, 1982.
 Cabilly et al., *Proc. Natl. Acad. Sci. USA*, 91:3273-3277, 1984.
 Cameron and Malmo, *Austr. Vet. J.*, 70:109-111, 1993.
 5 Capaldi et al., *Biochem. Biophys. Res. Comm.*, 76:425, 1977.
 Chardes et al., *FEBS Lett.*, 452(3):386-394, 1999.
 Colligan et al., In: *Current Protocols in Immunology*, Greene Publ. Assoc. Wiley Interscien, NY, 1993.
 Computational Molecular Biology, Lesk (Ed.), Oxford University Press, NY, 1988.
 Computer Analysis of Sequence Data, Part I, Griffin and Griffin (Eds.), Humana Press, NJ, 1994.
 10 Cumber et al., *J. Immunology*, 149B:120-126, 1992.
 Engvall, *Lancet*, 2(8000):1410, 1976.
 Engvall, *Med Biol.*, 55(4):193-200, 1977.
 Engvall, *Methods Enzymol.*, 70(A):419-39, 1980.
 Felsenstein, *Cladistics* 5:164-166, 1989.
 15 Green et al., *Theriogenology*, 63(5):1481-1503, 2005.
 Green et al., *Biol Reprod* 62:1624-1631, 2000.
 Green et al., *Biol Reprod* 60:1069-1077, 1999.
 Gripenberg et al., *Scand J Immunol.*, 7(2):151-7, 1978.
 Guruprasad et al. *Protein Eng* 9:849-856, 1996.
 20 Hall, *Nucl. Acids. Symp. Ser.* 41:95-98, 1999.
 Harlow and Lane, In: *Antibodies, a Laboratory, Manual*, Cold Spring Harbor Laboratory, pp 139-281, 1988.
 Hatzidakis et al., *J. Reprod Fertil.*, 98:235-240, 1993.
 Higgins and Sharp *CABIOS*. 5:151-153 (1989
 Holdsworth et al., *J. Endocrin.*, 95:7-12, 1982.
 25 Hughes et al., *Mol Biol Evol.* 20:1940-1945,2003.
 Humblot et al., *Theriogenol.*, 30:257-268, 1988.
 Kiracofe et al., *J. Anim. Sci.*, 71:2199-2205, 1993.
 Kohler and Milstein, *Nature*, 256:495-497,1975.
 Leibiger et al., *Biochem J.*, 338:529-538, 1999.
 30 Liu et al. *Cell Mol. Biol.*, 49(2):209-216, 2003.
 Makler et al., *Transfusion*, 21(3):303-312, 1981.
 Markusfeld et al., *Br. Vet. J.*, 146: 504-508, 1990.
 Mialon et al., *Reprod Nutr. Dev.*, 33:269-282, 1993.
 Mialon et al., *Reprod. Nutr. Dev.*, 34:65-72, 1994.
 35 Mo et al., *Eur. J. Immunol.*, 23:2503-2510, 1993.
 Nakamura et al., In: *Handbook of Experimental Immunology* (4th Ed.), Weir et al. (Eds.), 1:27, Blackwell Scientific Publ., Oxford, 1987.
 Neuberger et al., *Nature*, 314:268-270, 1985.
 Oltenacu et al., *J. Dairy Sci.*, 73:2826-2831, 1990.
 40 Pack et al., *Biochem.*, 31:1579-1584, 1992.
 WO 98/16832
 Sarngadharan et al., *Princess Takamatsu Symp.*, 15:301-8, 1984.
 Sasser et al., *Biol. Reprod.*, 35:936-942, 1986.
 Sequence Analysis in Molecular Biology, von Heinje (Ed.), Academic Press, 1987.
 45 Sequence Analysis Primer, Gribskov and Devereux (Eds.), Stockton Press, NY, 1991.
 Szafranska et al., *Biol. Reprod.*, 53:21-28, 1995.
 Wagner et al., *Science*, 260(5113):1510-1513, 1993
 Warnick et al., *Theriogenol.*, 44:811-825, 1995.
 Xie et al., *Biol. Reprod.*, 51:1145-1153, 1994.
 50 Xie et al., *Biol. Reprod.*, 54: 122-129, 1996.
 Xie et al., *Biol. Reprod.*, 57:1384-1393, 1997.
 Xie et al., *Proc. Natl. Acad. Sci. USA*, 88:10247-10251, 1991.
 Xie et al., *Proc. Natl. Acad. Sci. USA*, 94:12809-12816, 1997.
 Zoli et al., *Biol. Reprod.*, 45:1-10, 1991.
 55 Zoli et al., *Biol. Reprod.*, 46:83-92, 1992.

EP 2 225 274 B1

SEQUENCE LISTING

[0127]

5 <110> MONSANTO TECHNOLOGY LLC MATHIALAGAN, NAGAPPAN ROBERTS, R. MICHAEL McGRATH,
MICHAEL F. GREEN, JONATHAN

<120> COMPOSITIONS AND METHODS FOR EARLY PREGNANCY DIAGNOSIS

10 <130> MONS:108WO (37-21(54290))

<140> UNKNOWN

<141> 2008-12-12

15 <150> 61/013,603

<151> 2007-12-13

<160> 74

20 <170> PatentIn version 3.3

<210> 1

<211> 112

<212> PRT

25 <213> Artificial sequence

<220>

<223> Artificial antibody fragment light chain peptide sequence

30 <400> 1

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15

35 Asp Gln Ala Ser Ile Ser Cys Arg Ser Arg Gln Ser Ile Val His Ser
20 25 30

40 Asn Gly Asn Thr Tyr Leu Glu Trp Phe Leu Gln Lys Pro Gly Gln Ser
35 40 45

45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

50 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly
85 90 95

55 Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 2

EP 2 225 274 B1

<211> 124
<212> PRT
<213> Artificial sequence

5 <220>
<223> AArtificial antibody fragment heavy chain peptide sequence

<400> 2

10 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala
1 5 10 15
15 Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Ile Phe Ser Asn Tyr
20 25 30
20 Trp Met Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Leu Pro Gly Ser Asp Ile Thr Asn Tyr Asn Glu Lys Phe
50 55 60
25 Lys Asp Lys Ala Thr Phe Thr Ala Asp Ser Ser Ser Asn Thr Ala Tyr
65 70 75 80
30 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
35 Ala Arg Ala Gly Ser Gly Tyr Tyr Gly Val Tyr Tyr Tyr Ala Met Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

40 <210> 3
<211> 193
<212> PRT
<213> Artificial sequence

45 <220>
<223> Artificial antibody fragment light chain peptide sequence

<400> 3

50 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
55 Asp Gln Ala Ser Ile Ser Cys Arg Ser Arg Gln Ser Ile Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu Glu Trp Phe Leu Gln Lys Pro Gly Gln Ser

EP 2 225 274 B1

Trp Met Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile
35 40 45

5 Gly Glu Ile Leu Pro Gly Ser Asp Ile Thr Asn Tyr Asn Glu Lys Phe
50 55 60

10 Lys Asp Lys Ala Thr Phe Thr Ala Asp Ser Ser Ser Asn Thr Ala Tyr
65 70 75 80

15 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Ala Gly Ser Gly Tyr Tyr Gly Val Tyr Tyr Tyr Ala Met Asp
100 105 110

20 Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr
115 120 125

25 Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn
130 135 140

Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro
145 150 155 160

30 Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr
165 170 175

35 Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val
180 185 190

Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val
195 200 205

40 Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg
210 215 220

45 Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser
225 230 235 240

50 Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu
245 250 255

Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro
260 265 270

55 Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala

EP 2 225 274 B1

			275					280						285			
5	Gln	Thr	Gln	Pro	Arg	Glu	Glu	Gln	Phe	Asn	Ser	Thr	Phe	Arg	Ser	Val	
			290					295						300			
10	Ser	Glu	Leu	Pro	Ile	Met	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Phe	
	305					310					315					320	
15	Lys	Cys	Arg	Val	Asn	Ser	Ala	Ala	Phe	Pro	Ala	Pro	Ile	Glu	Lys	Thr	
					325					330					335		
20	Ile	Ser	Lys	Thr	Lys	Gly	Arg	Pro	Lys	Ala	Pro	Gln	Val	Tyr	Thr	Ile	
				340					345					350			
25	Pro	Pro	Pro	Lys	Glu	Gln	Met	Ala	Lys	Asp	Lys	Val	Ser	Leu	Thr	Cys	
				355				360					365				
30	Met	Ile	Thr	Asp	Phe	Phe	Pro	Glu	Asp	Ile	Thr	Val	Glu	Trp	Gln	Trp	
		370					375					380					
35	Asn	Gly	Gln	Pro	Ala	Glu	Asn	Tyr	Lys	Asn	Thr	Gln	Pro	Ile	Met	Asp	
	385					390					395				400		
40	Thr	Asp	Gly	Ser	Tyr	Phe	Val	Tyr	Ser	Lys	Leu	Asn	Val	Gln	Lys	Ser	
					405					410					415		
45	Asn	Trp	Glu	Ala	Gly	Asn	Thr	Phe	Thr	Cys	Ser	Val	Leu	His	Glu	Gly	
				420					425					430			
50	Leu	His	Asn	His	His	Thr	Glu	Lys	Ser	Leu	Ser	His	Ser	Pro	Gly	Lys	
			435					440					445				

<210> 5

<211> 695

<212> DNA

45 <213> Artificial sequence

<220>

<223> Nucleic acid sequence encoding 2D9 antibody fragment light chain

50 <400> 5

55

EP 2 225 274 B1

cggttcctgc ttccagcagt gatgttttga tgacccaaac tccactctcc ctgcctgtca 60
gtcttggaga tcaagcctcc atttcttgca gatctaggca gagcattgta catagtaatg 120
5 gaaacaccta tttagaatgg ttctctgcaga aaccaggcca gtctccaaag ctctgatct 180
acaaagtttc caaccgattt tctgggggtcc cagacagggt cagtggcagt ggatcagggg 240
cagatttcac actcaagatc agcagagtgg aggctgagga tctggggagt tattactgct 300
10 ttcaagggtc acatgttccg ctcacgttcg gtgctgggac caagctggag ctgaaacggg 360
ctgatgctgc accaactgta tccatcttcc caccatccag tgagcagtta acatctggag 420
15 gtgcctcagt cgtgtgcttc ttgaacaact tctaccccaa agacatcaat gtcaagtgga 480
agattgatgg cagtgaacga caaaatggcg tcctgaacag ttggactgat caggacagca 540
aagacagcac ctacagcatg agcagcacc tcacgttgac caaggacgag tatgaacgac 600
20 ataacagcta tacctgtgag gccactcaca agacatctac ttcaccatt gtcaagagct 660
tcaacaggaa tgagtgttag agacaaaggt cctga 695

25 <210> 6
<211> 1429
<212> DNA
<213> Artificial sequence
30 <220>
<223> Nucleic acid sequence encoding 2D9 antibody fragment heavy chain
<400> 6

35

40

45

50

55

EP 2 225 274 B1

gctacaggtg tccactccca ggttcagctg cagcagtctg gagctgagct gatgaagcct 60
 ggggcctcag tgaagatatc ctgcaaggct actggctaca tattcagtaa ctactggatg 120
 5 gagtgggtaa agcagaggcc tggacatggc cttgagtgga ttggagagat tttacctgga 180
 agtgatatta ctaactacaa tgagaagttc aaggacaagg ccacattcac tgcagattca 240
 tcctccaaca cggcctacat gcaactcagc agcctgacat ctgaggactc tgccgtctat 300
 10 tactgtgcaa gagctgggag tggttactac ggggtatatt actatgctat ggactactgg 360
 ggtcaaggaa cctcagtcac cgtctcctca gccaaaacga caccccatc tgtctatcca 420
 15 ctggcccctg gatctgctgc ccaaactaac tccatgggta cctggggatg cctgggtcaag 480
 ggctatthcc ctgagccagt gacagtgacc tggaaactctg gatccctgtc cagcgggtgtg 540
 cacacctthcc cagctgtcct gcagctgtac ctctacactc tgagcagctc agtgactgtc 600
 20 ccctccagca cctggcccag cgagaccgtc acctgcaacg ttgccaccg gccagcagc 660
 accaaggtgg acaagaaaat tgtgcccagg gattgtgggt gtaagccttg catatgtaca 720
 25 gtcccagaag tatcatctgt cttcatcttc cccccaaagc ccaaggatgt gctcaccatt 780
 actctgactc ctaaggtcac gtgtgttgtg gtagacatca gcaaggatga tcccagagtc 840
 cagttcagct ggtttgtaga tgatgtggag gtgcacacag ctgagacgca accccgggag 900
 30 gagcagttca acagcacttt ccgctcagtc agtgaacttc ccatcatgca ccaggactgg 960
 ctcaatggca aggagttcaa atgcagggtc aacagtgcag ctttcctgtc ccccatcgag 1020
 aaaaccatct ccaaaaccaa aggcagaccg aaggctccac aggtgtacac cattccacct 1080
 35 cccaaggagc agatggccaa ggataaagtc agtctgacct gcatgataac agacttcttc 1140
 cctgaagaca ttactgtgga gtggcagtggt aatgggcagc cagcggagaa ctacaagaac 1200
 40 actcagccca tcatggacac agatggctct tacttctctc acagcaagct caatgtgcag 1260
 aagagcaact gggaggcagg aaatactttc acctgctctg tgttacatga gggcctgcac 1320
 aaccaccata ctgagaagag cctctcccac tctctggta aatgatccca aagtccttgg 1380
 45 agccctctgg tcctacagga ctactgcagg tgtccactcc cctcaaca 1429

<210> 7

<211> 16

50 <212> PRT

<213> Bos taurus

<400> 7

55 Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Gly Leu Cys Leu Lys
 1 5 10 15

<210> 8

EP 2 225 274 B1

<211> 11
 <212> PRT
 <213> Bos taurus

5 <400> 8

Thr Phe Ser Gly Ala Phe Pro Ile Phe Asp Lys
 1 5 10

10 <210> 9
 <211> 16
 <212> PRT
 <213> Bos taurus

15 <400> 9

Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr Leu Ser Lys
 1 5 10 15

20 <210> 10
 <211> 16
 <212> PRT
 <213> Bos taurus

25 <400> 10

Asp Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His Arg
 1 5 10 15

30 <210> 11
 <211> 22
 <212> PRT
 <213> Bos taurus

35 <400> 11

Ala Leu Val Asp Thr Gly Thr Ser Asp Ile Val Gly Pro Ser Thr Leu
 1 5 10 15

40 Val Asn Asn Ile Trp Lys
 20

45 <210> 12
 <211> 7
 <212> PRT
 <213> Bos taurus

50 <400> 12

Tyr Phe Ser Val Phe Asp Arg
 1 5

55 <210> 13
 <211> 16
 <212> PRT
 <213> Bos taurus

EP 2 225 274 B1

<400> 13

5 Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Gly Leu Cys Leu Lys
1 5 10 15

<210> 14

<211> 11

<212> PRT

10 <213> Bos taurus

<400> 14

15 Thr Phe Ser Gly Ala Phe Pro Ile Phe Asp Lys
1 5 10

<210> 15

<211> 16

<212> PRT

20 <213> Bos taurus

<400> 15

25 Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr Leu Ser Lys
1 5 10 15

<210> 16

<211> 16

<212> PRT

30 <213> Bos taurus

<400> 16

35 Asp Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His Arg
1 5 10 15

<210> 17

<211> 22

40 <212> PRT

<213> Bos taurus

<400> 17

45 Ala Leu Val Asp Thr Gly Thr Ser Asp Ile Val Gly Pro Ser Thr Leu
1 5 10 15

50 Val Asn Asn Ile Trp Lys
20

<210> 18

<211> 7

<212> PRT

55 <213> Bos taurus

<400> 18

EP 2 225 274 B1

Tyr Phe Ser Val Phe Asp Arg
1 5

5
<210> 19
<211> 9
<212> PRT
<213> Bos taurus

10
<400> 19

Val Pro Gly Gln Ala Tyr Ile Leu Lys
1 5

15
<210> 20
<211> 8
<212> PRT
<213> Bos taurus

20
<400> 20

Leu Tyr Phe Ser Val Phe Asp Arg
1 5

25
<210> 21
<211> 10
<212> PRT
<213> Bos taurus

30
<400> 21

Thr Phe Ser Ile Thr Tyr Gly Ser Gly Arg

35
1 5 10

40
<210> 22
<211> 10
<212> PRT
<213> Bos taurus

45
<400> 22

Gly Glu Leu Asn Trp Ile Pro Leu Met Lys
1 5 10

50
<210> 23
<211> 18
<212> PRT
<213> Bos taurus

55
<400> 23

EP 2 225 274 B1

Leu Lys Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr Leu
1 5 10 15

5 Ser Lys

<210> 24

<211> 23

<212> PRT

10 <213> Bos taurus

<400> 24

15 Phe Asp Gly Val Leu Gly Leu Ser Tyr Thr Asn Ile Ser Pro Ser Gly
1 5 10 15

Ala Ile Pro Ile Phe Tyr Lys
20

20

<210> 25

<211> 16

<212> PRT

<213> Bos taurus

25

<400> 25

30 Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr Leu Ser Lys
1 5 10 15

<210> 26

<211> 16

<212> PRT

35 <213> Bos taurus

<400> 26

40 Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Gly Leu Cys Leu Lys
1 5 10 15

<210> 27

<211> 20

45 <212> PRT

<213> Bos taurus

<400> 27

50 Gly Glu Leu Asn Trp Val Pro Leu Ile Gln Val Gly Asp Trp Phe Val
1 5 10 15

55 His Met Asp Arg
20

<210> 28

<211> 18

EP 2 225 274 B1

<212> PRT

<213> Bos taurus

<400> 28

5

Leu Lys Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr Leu
1 5 10 15

10

Ser Lys

<210> 29

<211> 11

<212> PRT

15

<213> Bos taurus

<400> 29

20

Thr Phe Ser Gly Ala Phe Pro Ile Phe Asp Lys
1 5 10

<210> 30

<211> 16

<212> PRT

25

<213> Bos taurus

<400> 30

30

Asp Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His Arg
1 5 10 15

<210> 31

<211> 14

<212> PRT

35

<213> Bos taurus

<400> 31

40

Gln Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His Arg
1 5 10

<210> 32

<211> 7

<212> PRT

45

<213> Bos taurus

<400> 32

50

Tyr Phe Ser Val Phe Asp Arg
1 5

<210> 33

<211> 7

<212> PRT

55

<213> Bos taurus

<400> 33

EP 2 225 274 B1

Tyr Phe Ser Val Phe Asp Arg
1 5

5 <210> 34
<211> 9
<212> PRT
<213> Bos taurus

10 <400> 34

Gly Phe Leu Ala Tyr Asp Thr Val Arg
1 5

15 <210> 35
<211> 17
<212> PRT
<213> Bos taurus

20 <400> 35

Gln Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His Gln Tyr Tyr
1 5 10 15

25 Lys

30 <210> 36
<211> 17
<212> PRT
<213> Bos taurus

<400> 36

35 Gln Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His Gln Tyr Tyr
1 5 10 15

40 Lys

40 <210> 37
<211> 11
<212> PRT
<213> Bos taurus

45 <400> 37

Glu Thr Trp Ile Leu Gly Asp Ala Phe Leu Arg
1 5 10

50 <210> 38
<211> 19
<212> PRT
<213> Bos taurus

<400> 38

EP 2 225 274 B1

Asn Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His Gln
1 5 10 15

5 Tyr Tyr Lys

<210> 39

<211> 13

<212> PRT

10 <213> Bos taurus

<400> 39

15 Tyr Leu Pro Ser Ile Thr Phe Ile Ile Asn Gly Ile Lys
1 5 10

<210> 40

<211> 23

<212> PRT

20 <213> Bos taurus

<400> 40

25 Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Gly Leu Ser Val Val
1 5 10 15

Glu Tyr Gly Leu Glu Gly Arg
20

30

<210> 41

<211> 25

<212> PRT

<213> Bos taurus

35

<400> 41

40 Thr Val Ile Ala Cys Ser Asp Gly Cys Glu Ala Leu Val His Thr Gly
1 5 10 15

40

Thr Ser His Ile Glu Gly Pro Gly Arg
20 25

45 <210> 42

<211> 18

<212> PRT

<213> Bos taurus

50 <400> 42

Leu Lys Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr Leu
1 5 10 15

55

Ser Lys

<210> 43

EP 2 225 274 B1

<211> 14
 <212> PRT
 <213> Bos taurus

5 <400> 43

Gln Lys Gly Ser Val Val Met Phe Gly Gly Val Asp His Arg
 1 5 10

10 <210> 44
 <211> 16
 <212> PRT
 <213> Bos taurus

15 <400> 44

Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr Leu Ser Lys
 1 5 10 15

20 <210> 45
 <211> 8
 <212> PRT
 <213> Bos taurus

25 <400> 45

Val Tyr Phe Ser Val Phe Asp Arg
 1 5

30 <210> 46
 <211> 10
 <212> PRT
 <213> Bos taurus

35 <400> 46

Thr Phe Ser Ile Thr Tyr Gly Ser Gly Arg
 1 5 10

40 <210> 47
 <211> 20
 <212> PRT
 <213> Bos taurus

45 <400> 47

Val Val Ala Cys Ser Asp Gly Cys Glu Ala Val Val Asp Thr Gly Thr
 1 5 10 15

50 Ser Leu Ile Lys
 20

55 <210> 48
 <211> 21
 <212> PRT
 <213> Bos taurus

EP 2 225 274 B1

<400> 48

5 Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Gly Leu Ser Val Ser
1 5 10 15

Glu Tyr Gly Phe Lys
20

10 <210> 49

<211> 24

<212> PRT

<213> Bos taurus

15 <400> 49

Ala Tyr Asp Gly Ile Leu Gly Leu Asn Tyr Pro Asp Glu Ser Phe Ser
1 5 10 15

20 Glu Ala Ile Pro Ile Phe Asp Lys
20

25 <210> 50

<211> 16

<212> PRT

<213> Bos taurus

30 <400> 50

Phe Ser Ser Ser Thr Glu Thr Trp Leu Leu Gly Asp Ala Phe Leu Arg
1 5 10 15

35 <210> 51

<211> 380

<212> PRT

<213> Bos taurus

40 <400> 51

45

50

55

EP 2 225 274 B1

Met Lys Trp Leu Val Leu Leu Gly Leu Val Ala Phe Ser Glu Cys Ile
 1 5 10 15

5 Val Lys Ile Pro Leu Arg Arg Leu Lys Thr Met Arg Asn Val Val Ser
 20 25 30

10 Gly Lys Asn Met Leu Asn Asn Phe Leu Lys Glu His Ala Tyr Ser Leu
 35 40 45

15 Ser Gln Ile Ser Phe Arg Gly Ser Asn Leu Thr Thr His Pro Leu Arg
 50 55 60

20 Asn Ile Lys Asp Leu Val Tyr Met Gly Asn Ile Thr Ile Gly Thr Pro
 65 70 75 80

25 Pro Gln Glu Phe Gln Val Val Phe Asp Thr Ala Ser Ser Asp Leu Trp
 85 90 95

30 Phe Arg His Leu Gln Ser Ser Thr Phe Arg Leu Thr Asn Lys Thr Phe
 115 120 125

35 Arg Ile Thr Tyr Gly Ser Gly Arg Met Lys Gly Val Val Val His Asp
 130 135 140

40 Thr Val Arg Ile Gly Asn Leu Val Ser Thr Asp Gln Pro Phe Gly Leu
 145 150 155 160

45 Ser Ile Glu Glu Tyr Gly Phe Glu Gly Arg Ile Tyr Asp Gly Val Leu
 165 170 175

50 Gly Leu Asn Tyr Pro Asn Ile Ser Phe Ser Gly Ala Ile Pro Ile Phe
 180 185 190

55

EP 2 225 274 B1

Asp Lys Leu Lys Asn Gln Arg Ala Ile Ser Glu Pro Val Phe Ala Phe
 195 200 205
 5
 Tyr Leu Ser Lys Asp Glu Arg Glu Gly Ser Val Val Met Phe Gly Gly
 210 215 220
 10
 Val Asp His Arg Tyr Tyr Glu Gly Glu Leu Asn Trp Val Pro Leu Ile
 225 230 235 240
 15
 Gln Ala Gly Asp Trp Ser Val His Met Asp Arg Ile Ser Ile Glu Arg
 245 250 255
 20
 Lys Ile Ile Ala Cys Ser Asp Gly Cys Lys Ala Leu Val Asp Thr Gly
 260 265 270
 25
 Thr Ser Asp Ile Val Gly Pro Arg Arg Leu Val Asn Asn Ile His Arg
 275 280 285
 30
 Leu Ile Gly Ala Ile Pro Arg Gly Ser Glu His Tyr Val Pro Cys Ser
 290 295 300
 35
 Glu Val Asn Thr Leu Pro Ser Ile Val Phe Thr Ile Asn Gly Ile Asn
 305 310 315 320
 40
 Tyr Pro Val Pro Gly Arg Ala Tyr Ile Leu Lys Asp Asp Arg Gly Arg
 325 330 335
 45
 Cys Tyr Thr Thr Phe Gln Glu Asn Arg Val Ser Ser Ser Thr Glu Thr
 340 345 350
 50
 Trp Tyr Leu Gly Asp Val Phe Leu Arg Leu Tyr Phe Ser Val Phe Asp
 355 360 365
 55
 Arg Gly Asn Asp Arg Ile Gly Leu Ala Arg Ala Val
 370 375 380
 <210> 52
 <211> 380
 <212> PRT
 <213> Bos taurus
 <400> 52
 Met Lys Trp Leu Val Leu Leu Gly Leu Val Ala Phe Ser Glu Cys Ile
 1 5 10 15

EP 2 225 274 B1

Val Lys Ile Pro Leu Arg Arg Val Lys Thr Met Thr Lys Thr Leu Ser
20 25 30

5 Gly Lys Asn Met Leu Asn Asn Phe Val Lys Glu His Ala Tyr Arg Leu
35 40 45

10 Ser Gln Ile Ser Phe Arg Gly Ser Asn Leu Thr Ile His Pro Leu Arg
50 55 60

15 Asn Ile Arg Asp Phe Phe Tyr Val Gly Asn Ile Thr Ile Gly Thr Pro
65 70 75 80

Pro Gln Glu Phe Gln Val Ile Phe Asp Thr Gly Ser Ser Glu Leu Trp
85 90 95

20 Val Pro Ser Ile Phe Cys Asn Ser Ser Thr Cys Ser Lys His Asp Arg
100 105 110

25 Phe Arg His Leu Glu Ser Ser Thr Phe Arg Leu Ser Arg Arg Thr Phe
115 120 125

Ser Ile Thr Tyr Gly Ser Gly Arg Ile Glu Ala Leu Val Val His Asp
130 135 140

30 Thr Val Arg Ile Gly Asp Leu Val Ser Thr Asp Gln Gln Phe Gly Leu
145 150 155 160

35 Cys Leu Glu Glu Ser Gly Phe Glu Gly Met Arg Phe Asp Gly Val Leu
165 170 175

Gly Leu Ser Tyr Thr Asn Ile Ser Pro Ser Gly Ala Ile Pro Ile Phe
180 185 190

40 Tyr Lys Leu Lys Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe
195 200 205

45 Tyr Leu Ser Lys Asp Glu Arg Glu Gly Ser Val Val Met Phe Gly Gly
210 215 220

50 Ala Asp His Arg Tyr Tyr Lys Gly Glu Leu Asn Trp Ile Pro Leu Met
225 230 235 240

Lys Ala Gly Asp Trp Ser Val His Met Asp Arg Ile Ser Met Lys Arg
245 250 255

55 Lys Val Ile Ala Cys Ser Gly Gly Cys Lys Ala Leu Val Asp Thr Gly

EP 2 225 274 B1

					260					265					270	
5	Ser	Ser	Asp	Ile	Val	Gly	Pro	Ser	Thr	Leu	Val	Asn	Asn	Ile	Trp	Lys
			275					280					285			
10	Leu	Ile	Gly	Ala	Thr	Pro	Gln	Gly	Ser	Glu	His	Tyr	Val	Ser	Cys	Ser
		290					295					300				
15	Ala	Val	Asn	Ser	Leu	Pro	Ser	Ile	Ile	Phe	Thr	Ile	Lys	Ser	Asn	Asn
	305					310					315					320
20	Tyr	Arg	Val	Pro	Gly	Gln	Ala	Tyr	Ile	Leu	Lys	Asp	Ser	Arg	Gly	Arg
					325					330					335	
25	Trp	Ile	Leu	Gly	Asp	Val	Phe	Leu	Arg	Leu	Tyr	Phe	Ser	Val	Phe	Asp
			355					360					365			
30	Arg	Arg	Lys	Asp	Arg	Ile	Gly	Leu	Ala	Thr	Lys	Val				
		370					375					380				
35	<210>	53														
	<211>	379														
	<212>	PRT														
	<213>	Bos taurus														
40	<400>	53														
45	Met	Lys	Trp	Leu	Val	Leu	Leu	Gly	Leu	Val	Ala	Phe	Ser	Glu	Cys	Ile
	1				5					10					15	
50	Val	Lys	Ile	Pro	Leu	Arg	Arg	Val	Lys	Thr	Met	Arg	Asn	Ala	Ile	Ser
				20					25					30		
55	Gly	Lys	Asn	Thr	Leu	Asn	Asn	Ile	Leu	Lys	Glu	His	Ala	Tyr	Arg	Leu
			35					40					45			
60	Pro	Gln	Ile	Ser	Phe	Arg	Gly	Ser	Asn	Leu	Thr	His	Pro	Leu	Arg	Asn
		50					55					60				
65	Ile	Arg	Asp	Leu	Phe	Tyr	Val	Gly	Asn	Ile	Thr	Ile	Gly	Thr	Pro	Pro
	65					70					75					80
70	Gln	Glu	Phe	Gln	Val	Ile	Phe	Asp	Thr	Gly	Ser	Ser	Asp	Leu	Trp	Val
				85						90					95	

EP 2 225 274 B1

Ala Ser Ile Phe Cys Asn Ser Ser Ser Cys Ala Ala His Val Arg Phe
100 105 110

5 Arg His His Gln Ser Ser Thr Phe Arg Pro Thr Asn Lys Thr Phe Arg
115 120 125

10 Ile Thr Tyr Gly Ser Gly Arg Met Lys Gly Val Val Val His Asp Thr
130 135 140

15 Val Arg Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Gly Leu Cys
145 150 155 160

Leu Lys Asp Ser Gly Phe Lys Gly Ile Pro Phe Asp Gly Ile Leu Gly
165 170 175

20 Leu Ser Tyr Pro Asn Lys Thr Phe Ser Gly Ala Phe Pro Ile Phe Asp
180 185 190

25 Lys Leu Lys Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr
195 200 205

30 Leu Ser Lys Asp Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly Val
210 215 220

35 Asp His Arg Tyr Tyr Lys Gly Glu Leu Asn Trp Val Pro Leu Ile Gln
225 230 235 240

Val Gly Asp Trp Phe Val His Met Asp Arg Thr Thr Met Lys Arg Lys
245 250 255

40 Val Ile Ala Cys Ser Asp Gly Cys Lys Ala Leu Val Asp Thr Gly Thr
260 265 270

45 Ser Asp Ile Val Gly Pro Ser Thr Leu Val Asn Asn Ile Trp Lys Leu
275 280 285

Ile Arg Ala Arg Pro Leu Gly Pro Gln Tyr Phe Val Ser Cys Ser Ala
290 295 300

50 Val Asn Thr Leu Pro Ser Ile Ile Phe Thr Ile Asn Gly Ile Asn Tyr
305 310 315 320

55 Arg Leu Pro Ala Arg Ala Tyr Ile His Lys Asp Ser Arg Gly Arg Cys
325 330 335

EP 2 225 274 B1

Tyr Thr Ala Phe Lys Glu His Arg Phe Ser Ser Pro Ile Glu Thr Trp
340 345 350

5 Leu Leu Gly Asp Val Phe Leu Arg Arg Tyr Phe Ser Val Phe Asp Arg
355 360 365

10 Gly Asn Asp Arg Ile Gly Leu Ala Arg Ala Val
370 375

<210> 54

<211> 379

<212> PRT

15 <213> Bos taurus

<400> 54

20

25

30

35

40

45

50

55

EP 2 225 274 B1

Met Lys Trp Leu Val Leu Leu Gly Leu Val Ala Phe Ser Glu Cys Ile
1 5 10

5 Val Lys Ile Pro Leu Arg Arg Val Lys Thr Met Arg Asn Ala Ile Ser
20 25 30

10 Gly Lys Asn Thr Leu Asn Asn Ile Leu Lys Glu His Ala Tyr Arg Leu
35 40 45

15 Pro Gln Ile Ser Phe Arg Gly Ser Asn Leu Thr His Pro Leu Arg Asn
50 55 60

Ile Arg Asp Leu Phe Tyr Val Gly Asn Ile Thr Ile Gly Thr Pro Pro
65 70 75 80

20 Gln Glu Phe Gln Val Ile Phe Asp Thr Gly Ser Ser Asp Leu Trp Val
85 90 95

25 Ala Ser Ile Phe Cys Asn Ser Ser Ser Cys Ala Ala His Val Arg Phe
100 105 110

30 Arg His His Gln Ser Ser Thr Phe Arg Pro Thr Asn Lys Thr Phe Arg
115 120 125

Ile Thr Tyr Gly Ser Gly Arg Met Lys Gly Val Val Val His Asp Thr
130 135 140

35 Val Arg Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Gly Leu Cys
145 150 155 160

40 Leu Lys Asp Ser Gly Phe Lys Gly Ile Pro Phe Asp Gly Ile Leu Gly
165 170 175

45

50

55

EP 2 225 274 B1

Leu Ser Tyr Pro Asn Lys Thr Phe Ser Gly Ala Phe Pro Ile Phe Asp
 180 185 190
 5
 Lys Leu Lys Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr
 195 200 205
 10
 Leu Ser Lys Asp Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly Val
 210 215 220
 15
 Asp His Arg Tyr Tyr Lys Gly Glu Leu Asn Trp Val Pro Leu Ile Gln
 225 230 235 240
 20
 Val Gly Asp Trp Phe Val His Met Asp Arg Ile Thr Met Lys Arg Lys
 245 250 255
 25
 Val Ile Ala Cys Ser Asp Gly Cys Lys Ala Leu Val Asp Thr Gly Thr
 260 265 270
 30
 Ser Asp Ile Val Gly Pro Ser Thr Leu Val Asn Asn Ile Trp Lys Leu
 275 280 285
 35
 Ile Arg Ala Arg Pro Leu Gly Pro Gln Tyr Phe Val Ser Cys Ser Ala
 290 295 300
 40
 Val Asn Thr Leu Pro Ser Ile Ile Phe Thr Ile Asn Gly Ile Asn Tyr
 305 310 315 320
 45
 Arg Leu Pro Ala Arg Ala Tyr Ile His Lys Asp Ser Arg Gly Arg Cys
 325 330 335
 50
 Tyr Thr Ala Phe Lys Glu His Arg Phe Ser Ser Pro Ile Glu Thr Trp
 340 345 350
 55
 Leu Leu Gly Asp Val Phe Leu Arg Arg Tyr Phe Ser Val Phe Asp Arg
 355 360 365
 Gly Asn Asp Arg Ile Gly Leu Ala Arg Ala Val
 370 375
 <210> 55
 <211> 379
 <212> PRT
 <213> Bos taurus
 <400> 55

EP 2 225 274 B1

Met Lys Trp Ile Val Leu Leu Gly Leu Val Ala Phe Ser Glu Cys Ile
1 5 10

5 Val Lys Ile Pro Leu Arg Gln Val Lys Thr Met Arg Lys Thr Leu Ser
20 25 30

10 Gly Lys Asn Met Leu Lys Asn Phe Leu Lys Glu His Pro Tyr Arg Leu
35 40 45

15 Ser Gln Ile Ser Phe Arg Gly Ser Asn Leu Thr Ile His Pro Leu Arg
50 55 60

20 Asn Ile Met Asn Leu Val Tyr Val Gly Asn Ile Thr Ile Gly Thr Pro
65 70 75 80

25 Pro Gln Glu Phe Gln Val Val Phe Asp Thr Gly Ser Ser Asp Leu Trp
85 90 95

30 Val Pro Ser Phe Cys Thr Met Pro Ala Cys Ser Ala Pro Val Trp Phe
100 105 110

35 Arg Gln Leu Gln Ser Ser Thr Phe Gln Pro Thr Asn Lys Thr Phe Thr
115 120 125

40 Ile Thr Tyr Gly Ser Gly Ser Met Lys Gly Phe Leu Ala Tyr Asp Thr
130 135 140

45 Val Arg Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Gly Leu Ser
145 150 155 160

50 Val Val Glu Tyr Gly Leu Glu Gly Arg Asn Tyr Asp Gly Val Leu Gly
165 170 175

55 Leu Asn Tyr Pro Asn Ile Ser Phe Ser Gly Ala Ile Pro Ile Phe Asp
180 185 190

60 Asn Leu Lys Asn Gln Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr
195 200 205

65 Leu Ser Lys Asn Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly Val
210 215 220

70 Asp His Gln Tyr Tyr Lys Gly Glu Leu Asn Trp Ile Pro Leu Ile Glu
225 230 235 240

75 Ala Gly Glu Trp Arg Val His Met Asp Arg Ile Ser Met Lys Arg Thr

EP 2 225 274 B1

				245					250					255		
5	Val	Ile	Ala	Cys	Ser	Asp	Gly	Cys	Glu	Ala	Leu	Val	His	Thr	Gly	Thr
				260					265					270		
10	Ser	His	Ile	Glu	Gly	Pro	Gly	Arg	Leu	Val	Asn	Asn	Ile	His	Arg	Leu
			275					280					285			
15	Ile	Arg	Thr	Arg	Pro	Phe	Asp	Ser	Lys	His	Tyr	Val	Ser	Cys	Phe	Ala
		290					295					300				
20	Thr	Lys	Tyr	Leu	Pro	Ser	Ile	Thr	Phe	Ile	Ile	Asn	Gly	Ile	Lys	Tyr
	305					310						315				320
25	Pro	Met	Thr	Ala	Arg	Ala	Tyr	Ile	Phe	Lys	Asp	Ser	Arg	Gly	Arg	Cys
				325						330					335	
30	Tyr	Ser	Ala	Phe	Lys	Glu	Asn	Thr	Val	Arg	Thr	Ser	Arg	Glu	Thr	Trp
			340						345					350		
35	Ile	Leu	Gly	Asp	Ala	Phe	Leu	Arg	Arg	Tyr	Phe	Ser	Val	Phe	Asp	Arg
			355					360					365			
40	Gly	Asn	Asp	Arg	Ile	Gly	Leu	Ala	Arg	Ala	Val					
		370					375									
45	<210>	56														
	<211>	379														
	<212>	PRT														
	<213>	Bos taurus														
50	<400>	56														
	Met	Lys	Trp	Ile	Val	Leu	Leu	Gly	Leu	Val	Ala	Phe	Ser	Glu	Cys	Ile
	1				5					10					15	
55	Val	Lys	Ile	Pro	Leu	Arg	Gln	Val	Lys	Thr	Met	Arg	Lys	Thr	Leu	Ser
				20					25					30		
60	Gly	Lys	Asn	Met	Leu	Lys	Asn	Phe	Leu	Lys	Glu	His	Pro	Tyr	Arg	Leu
			35					40					45			
65	Ser	Gln	Ile	Ser	Phe	Arg	Gly	Ser	Asn	Leu	Thr	Ile	His	Pro	Leu	Arg
		50					55					60				
70	Asn	Ile	Met	Asn	Leu	Val	Tyr	Val	Gly	Asn	Ile	Thr	Ile	Gly	Thr	Pro
	65					70					75					80

EP 2 225 274 B1

Pro Gln Glu Phe Gln Val Val Phe Asp Thr Gly Ser Ser Asp Leu Trp
85 90 95

5 Val Pro Ser Phe Cys Thr Met Pro Ala Cys Ser Ala Pro Val Trp Phe
100 105 110

10 Arg Gln Leu Gln Ser Ser Thr Phe Gln Pro Thr Asn Lys Thr Phe Thr
115 120 125

15 Ile Thr Tyr Gly Ser Gly Ser Met Lys Gly Phe Leu Ala Tyr Asp Thr
130 135 140

Val Arg Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Gly Leu Ser
145 150 155 160

20 Val Val Glu Tyr Gly Leu Glu Gly Arg Asn Tyr Asp Gly Val Leu Gly
165 170 175

25 Leu Asn Tyr Pro Asn Ile Ser Phe Ser Gly Ala Ile Pro Ile Phe Asp
180 185 190

30 Asn Leu Lys Asn Gln Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr
195 200 205

Leu Ser Lys Asn Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly Val
210 215 220

35 Asp His Gln Tyr Tyr Lys Gly Glu Leu Asn Trp Ile Pro Leu Ile Glu
225 230 235 240

40 Ala Gly Glu Trp Arg Val His Met Asp Arg Ile Ser Met Lys Arg Thr
245 250 255

45 Val Ile Ala Cys Ser Asp Gly Cys Glu Ala Leu Val His Thr Gly Thr
260 265 270

Ser His Ile Glu Gly Pro Gly Arg Leu Val Asn Asn Ile His Arg Leu
275 280 285

50 Ile Arg Thr Arg Pro Phe Asp Ser Lys His Tyr Val Ser Cys Phe Ala
290 295 300

55 Thr Lys Tyr Leu Pro Ser Ile Thr Phe Ile Ile Asn Gly Ile Lys Tyr
305 310 315 320

EP 2 225 274 B1

Pro Met Thr Ala Arg Ala Tyr Ile Phe Lys Asp Ser Arg Gly Arg Cys
325 330 335

5 Tyr Ser Ala Phe Lys Glu Asn Thr Val Arg Thr Ser Arg Glu Thr Trp
340 345 350

10 Ile Leu Gly Asp Ala Phe Leu Arg Arg Tyr Phe Ser Val Phe Asp Arg
355 360 365

15 Gly Asn Asp Arg Ile Gly Leu Ala Gln Ala Val
370 375

<210> 57

<211> 380

<212> PRT

<213> Bos taurus

20

<400> 57

25

30

35

40

45

50

55

EP 2 225 274 B1

Met Lys Trp Leu Val Leu Leu Gly Leu Val Ala Phe Ser Glu Cys Ile
 1 5 10 15

5 Val Lys Ile Pro Leu Arg Arg Val Lys Thr Met Arg Lys Thr Leu Ser
 20 25 30

10 Gly Lys Asn Thr Leu Asn Asn Phe Leu Lys Glu His Pro Tyr Arg Leu
 35 40 45

15 Ser His Ile Ser Phe Arg Gly Ser Asn Leu Thr Thr Leu Pro Leu Arg
 50 55 60

20 Asn Ile Arg Asp Met Leu Tyr Val Gly Asn Ile Thr Ile Gly Thr Pro
 65 70 75 80

25 Pro Gln Glu Phe Gln Val Val Phe Asp Thr Gly Ser Ser Asp Leu Trp
 85 90 95

30 Val Pro Ser Asp Phe Cys Thr Ser Pro Ala Cys Ser Thr His Val Arg
 100 105 110

35 Phe Arg His Phe Gln Ser Ser Thr Phe Arg Pro Thr Thr Lys Thr Phe
 115 120 125

40 Arg Ile Ile Tyr Gly Ser Gly Arg Met Lys Gly Val Val Ala His Asp
 130 135 140

45 Thr Val Arg Ile Gly Asn Leu Val Ser Thr Asp Gln Pro Phe Gly Leu
 145 150 155 160

50

55

EP 2 225 274 B1

Ser Met Ala Glu Tyr Gly Leu Glu Ser Arg Arg Phe Asp Gly Ile Leu
165 170 175

5 Gly Leu Asn Tyr Pro Asn Leu Ser Cys Ser Gly Ala Ile Pro Ile Phe
180 185 190

10 Asp Lys Leu Lys Asn Gln Gly Ala Ile Ser Asp Pro Ile Phe Ala Phe
195 200 205

15 Tyr Leu Ser Lys Asp Lys Arg Glu Gly Ser Val Val Met Phe Gly Gly
210 215 220

20 Val Asp His Arg Tyr Tyr Lys Gly Glu Leu Asn Trp Val Pro Leu Ile
225 230 235 240

25 Arg Ala Gly Asp Trp Ile Val His Val Asp Arg Ile Thr Met Lys Arg
245 250 255

30 Glu Val Ile Ala Cys Ser Asp Gly Cys Ala Ala Leu Val Asp Thr Gly
260 265 270

35 Thr Ser Leu Ile Gln Gly Pro Gly Arg Val Ile Asp Asn Ile His Lys
275 280 285

40 Leu Ile Gly Ala Thr Pro Arg Gly Ser Lys His Tyr Val Ser Cys Ser
290 295 300

45 Val Val Asn Thr Leu Pro Ser Ile Ile Phe Thr Ile Asn Gly Ile Asn
305 310 315 320

50 Tyr Pro Val Pro Ala Pro Ala Tyr Ile Leu Lys Asp Ser Arg Gly Tyr
325 330 335

55 Cys Tyr Thr Ala Phe Lys Glu Gln Arg Val Arg Arg Ser Thr Glu Ser
340 345 350

Trp Leu Leu Gly Asp Val Phe Leu Arg Leu Tyr Phe Ser Val Phe Asp
355 360 365

Arg Gly Asn Asp Arg Ile Gly Leu Ala Arg Ala Val
370 375 380

<210> 58
<211> 380
<212> PRT
<213> Bos taurus

EP 2 225 274 B1

<400> 58

5 Met Lys Trp Leu Val Leu Leu Trp Leu Val Ala Phe Ser Glu Cys Ile
1 5 10

10 Val Lys Ile Pro Leu Arg Gln Val Lys Thr Met Arg Lys Thr Leu Ser
20 25 30

15 Gly Lys Asn Thr Leu Asn Asn Phe Leu Lys Glu His Thr Tyr Ser Leu
35 40 45

20 Ser Gln Ile Ser Ser Arg Gly Ser Asn Leu Thr Ile His Pro Leu Arg
50 55 60

25 Asn Ile Met Asp Met Leu Tyr Val Gly Asn Ile Thr Ile Gly Thr Pro
65 70 75 80

30 Pro Gln Glu Phe Gln Val Val Phe Asp Thr Gly Ser Ser Asp Leu Trp
85 90 95

35 Val Pro Ser Val Phe Cys Gln Ser Leu Ala Cys Ala Thr Lys Val Met
100 105 110

40 Phe Ile His Leu His Ser Ser Thr Phe Arg His Thr Gln Lys Val Phe
115 120 125

45 Asn Ile Lys Tyr Asn Thr Gly Arg Met Lys Gly Leu Leu Val Tyr Asp
130 135 140

50 Thr Val Arg Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Cys Ile
145 150 155 160

55 Ser Leu Ala Glu Val Gly Phe Asp Gly Ile Pro Phe Asp Gly Val Leu
165 170 175

60 Gly Leu Asn Tyr Pro Asn Met Ser Phe Ser Gly Ala Ile Pro Ile Phe
180 185 190

65 Asp Asn Leu Lys Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe
195 200 205

70 Tyr Leu Ser Lys Asp Lys Arg Glu Gly Ser Val Val Met Phe Gly Gly
210 215 220

75 Val Asp His Arg Tyr Tyr Lys Gly Glu Leu Asn Trp Val Pro Leu Ile

EP 2 225 274 B1

	225				230					235				240		
5	Gln	Ala	Gly	Gly	Trp	Thr	Val	His	Val	Asp	Arg	Ile	Ser	Met	Lys	Arg
					245					250					255	
10	Lys	Ile	Ile	Ala	Cys	Ser	Gly	Gly	Cys	Glu	Ala	Leu	Val	Asp	Thr	Gly
				260					265					270		
15	Thr	Ala	Leu	Ile	Lys	Gly	Pro	Arg	Arg	Leu	Val	Asn	Asn	Ile	Gln	Lys
			275					280					285			
20	Leu	Ile	Gly	Thr	Thr	Pro	Arg	Gly	Ser	Lys	His	Tyr	Val	Ser	Cys	Ser
		290					295					300				
25	Val	Val	Asn	Thr	Leu	Pro	Ser	Ile	Ile	Phe	Thr	Ile	Asn	Gly	Ile	Asn
	305					310					315					320
30	Tyr	Pro	Val	Pro	Ala	Arg	Ala	Tyr	Ile	Leu	Lys	Asp	Ser	Glu	Ser	Asn
					325					330					335	
35	Cys	Tyr	Thr	Thr	Phe	Lys	Glu	Asn	Thr	Val	Arg	Thr	Ser	Arg	Glu	Thr
				340					345					350		
40	Trp	Ile	Leu	Gly	Asp	Val	Phe	Pro	Arg	Leu	Tyr	Phe	Ser	Val	Phe	Asp
			355					360					365			
45	Arg	Gly	Asn	Asp	Arg	Ile	Gly	Leu	Ala	Arg	Ala	Val				
		370					375					380				
50	<210>	59														
	<211>	380														
55	<212>	PRT														
	<213>	Bos taurus														
60	<400>	59														
65	Met	Lys	Trp	Leu	Val	Leu	Leu	Trp	Leu	Val	Ala	Phe	Ser	Glu	Cys	Ile
	1				5					10					15	
70	Val	Lys	Ile	Pro	Leu	Arg	Gln	Val	Lys	Thr	Met	Arg	Lys	Thr	Leu	Ser
				20					25					30		
75	Gly	Lys	Asn	Thr	Leu	Asn	Asn	Phe	Leu	Lys	Glu	His	Thr	Tyr	Ser	Leu
			35					40					45			
80	Ser	Gln	Ile	Ser	Ser	Arg	Gly	Ser	Asn	Leu	Thr	Ile	His	Pro	Leu	Arg
		50					55					60				

EP 2 225 274 B1

Asn Ile Met Asp Met Leu Tyr Val Gly Asn Ile Thr Ile Gly Thr Pro
65 70 75 80

5 Pro Gln Glu Phe Gln Val Val Phe Asp Thr Gly Ser Ser Asp Leu Trp
85 90 95

10 Val Pro Ser Val Phe Cys Gln Ser Leu Ala Cys Ala Thr Lys Val Met
100 105 110

15 Phe Ile His Leu Tyr Ser Ser Thr Phe Arg His Thr Gln Lys Val Phe
115 120 125

20 Asn Ile Lys Tyr Asn Thr Gly Arg Met Lys Gly Leu Leu Val Tyr Asp
130 135 140

25 Thr Val Arg Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Cys Ile
145 150 155 160

30 Ser Leu Ala Glu Val Gly Phe Asp Gly Ile Pro Phe Asp Gly Val Leu
165 170 175

35 Gly Leu Asn Tyr Pro Asn Met Ser Phe Ser Gly Ala Ile Pro Ile Phe
180 185 190

40 Asp Asn Leu Lys Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe
195 200 205

45 Tyr Leu Ser Lys Asp Lys Arg Glu Gly Ser Val Val Met Phe Gly Gly
210 215 220

50 Val Asp His Arg Tyr Tyr Lys Gly Glu Leu Asn Trp Val Pro Leu Ile
225 230 235 240

55 Gln Ala Gly Gly Trp Thr Val His Val Asp Arg Ile Ser Met Lys Arg
245 250 255

Lys Ile Ile Ala Cys Ser Gly Gly Cys Glu Ala Leu Val Asp Thr Gly
260 265 270

Thr Ala Leu Ile Lys Gly Pro Arg Arg Leu Val Asn Asn Ile Gln Lys
275 280 285

Leu Ile Gly Thr Thr Pro Arg Gly Ser Lys His Tyr Val Ser Cys Ser
290 295 300

EP 2 225 274 B1

Val Val Asn Thr Leu Pro Ser Ile Ile Phe Thr Ile Asn Gly Ile Asn
305 310 315 320

5 Tyr Pro Val Pro Ala Arg Ala Tyr Ile Leu Lys Asp Ser Glu Ser His
325 330 335

10 Cys Tyr Thr Ala Phe Lys Glu Asn Thr Val Arg Thr Ser Arg Glu Thr
340 345 350

15 Trp Ile Leu Gly Asp Val Phe Leu Arg Leu Tyr Phe Ser Val Phe Asp
355 360 365

Arg Gly Asn Asp Arg Ile Gly Leu Ala Arg Ala Val
370 375 380

20 <210> 60
<211> 380
<212> PRT
<213> Bos taurus

25 <400> 60

30

35

40

45

50

55

EP 2 225 274 B1

Met Lys Trp Leu Val Val Leu Gly Leu Val Ala Phe Ser Glu Cys Ile
 1 5 10 15

5 Val Lys Ile Pro Leu Arg Arg Val Lys Thr Met Arg Lys Ala Leu Ser
 20 25 30

10 Gly Lys Asn Met Leu Asn Asn Phe Leu Lys Glu His Ala Tyr Arg Leu
 35 40 45

15 Ser Gln Ile Ser Phe Arg Gly Ser Asn Leu Thr Ser His Pro Leu Arg
 50 55 60

20 Asn Ile Lys Asp Leu Val Tyr Leu Ala Asn Ile Thr Ile Gly Thr Pro
 65 70 75 80

25 Pro Gln Glu Phe Gln Val Phe Leu Asp Thr Gly Ser Ser Asp Leu Trp
 85 90 95

30 Val Pro Ser Asp Phe Cys Thr Ser Pro Gly Cys Ser Lys His Val Arg
 100 105 110

35 Phe Arg His Leu Gln Ser Ser Thr Phe Arg Leu Thr Asn Lys Thr Phe
 115 120 125

40 Ser Ile Thr Tyr Gly Ser Gly Arg Ile Lys Gly Val Val Ala His Asp
 130 135 140

45

50

55

EP 2 225 274 B1

Thr Val Arg Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Ser Leu
 145 150 155 160
 5 Ser Met Ala Glu Tyr Gly Leu Glu His Ile Pro Phe Asp Gly Ile Leu
 165 170 175
 10 Gly Leu Asn Tyr Pro Asn Val Ser Ser Ser Gly Ala Ile Pro Ile Phe
 180 185 190
 15 Asp Lys Leu Lys Asn Gln Gly Ala Ile Ser Glu Pro Val Phe Ala Phe
 195 200 205
 Tyr Leu Ser Lys Asp Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly
 210 215 220
 20 Val Asp His Arg Tyr Tyr Arg Gly Lys Leu Asn Trp Val Pro Leu Ile
 225 230 235 240
 25 Gln Ala Gly Asn Trp Ile Ile His Met Asp Ser Ile Ser Ile Glu Arg
 245 250 255
 30 Lys Val Ile Ala Cys Ser Gly Gly Cys Val Ala Phe Val Asp Ile Gly
 260 265 270
 Thr Ala Phe Ile Glu Gly Pro Lys Pro Leu Val Asp Asn Met Gln Lys
 275 280 285
 35 Leu Ile Arg Ala Lys Pro Trp Arg Ser Lys His Tyr Val Ser Cys Ser
 290 295 300
 40 Ala Val Asn Thr Leu Pro Ser Ile Thr Phe Thr Ile Asn Gly Ile Asn
 305 310 315 320
 45 Tyr Pro Val Pro Gly Arg Ala Tyr Ile Leu Lys Asp Ser Arg Arg Arg
 325 330 335
 Cys Tyr Ser Thr Phe Lys Glu Ile Pro Leu Ser Pro Thr Thr Glu Phe
 340 345 350
 50 Trp Met Leu Gly Asp Val Phe Leu Arg Leu Tyr Phe Ser Val Phe Asp
 355 360 365
 55 Arg Gly Asn Asp Arg Ile Gly Leu Ala Arg Ala Val
 370 375 380

<210> 61

EP 2 225 274 B1

<211> 380
 <212> PRT
 <213> Bos taurus

5 <400> 61

10	Met	Lys	Trp	Leu	Val	Leu	Leu	Gly	Leu	Val	Ala	Phe	Ser	Glu	Cys	Ile
	1				5					10					15	
15	Phe	Lys	Ile	Pro	Leu	Arg	Arg	Val	Lys	Thr	Met	Arg	Lys	Thr	Leu	Ser
				20					25					30		
20	Gly	Lys	Asn	Met	Leu	Asn	Asn	Phe	Leu	Lys	Glu	His	Pro	Tyr	Lys	Leu
			35					40					45			
25	Ser	Gln	Ile	Ser	Phe	Arg	Gly	Ser	Asn	Leu	Thr	Thr	Leu	Pro	Leu	Arg
		50					55					60				
30	Asn	Ile	Trp	Asp	Ile	Phe	Tyr	Ile	Gly	Thr	Ile	Thr	Ile	Gly	Thr	Pro
	65					70					75					80
35	Pro	Gln	Glu	Phe	Gln	Val	Val	Phe	Asp	Thr	Ala	Ser	Ser	Asp	Leu	Trp
					85					90					95	
40	Val	Pro	Ser	Ile	Ile	Cys	Asn	Ser	Ser	Thr	Cys	Ser	Thr	His	Val	Arg
				100						105				110		
45	Phe	Arg	His	Arg	Gln	Ser	Ser	Thr	Phe	Arg	Leu	Thr	Asn	Lys	Thr	Phe
			115					120					125			
50	Gly	Ile	Thr	Tyr	Gly	Ser	Gly	Arg	Met	Lys	Gly	Val	Val	Val	His	Asp
		130					135					140				
55	Thr	Val	Arg	Ile	Gly	Asp	Leu	Val	Ser	Thr	Asp	Gln	Pro	Phe	Gly	Leu
	145					150					155					160
60	Ser	Val	Ala	Glu	Tyr	Gly	Phe	Glu	Gly	Arg	Arg	Phe	Asp	Gly	Val	Leu
					165					170					175	
65	Gly	Leu	Asn	Tyr	Pro	Asn	Ile	Ser	Phe	Ser	Lys	Ala	Ile	Pro	Ile	Phe
			180						185					190		
70	Asp	Lys	Leu	Lys	Asn	Glu	Gly	Ala	Ile	Ser	Glu	Pro	Val	Phe	Ala	Phe
			195					200					205			
75	Tyr	Leu	Ser	Lys	Asp	Lys	Gln	Lys	Gly	Ser	Val	Val	Met	Phe	Gly	Gly

EP 2 225 274 B1

	210		215		220												
5	Val 225	Asp	His	Arg	Tyr	Tyr 230	Lys	Gly	Glu	Leu	Asn 235	Trp	Val	Pro	Leu	Ile 240	
10	Arg	Ala	Gly	Asp	Trp 245	Ser	Val	His	Val	Asp 250	Arg	Ile	Thr	Met	Lys 255	Gly	
15	Glu	Val	Ile	Gly 260	Cys	Ser	Asp	Gly	Cys 265	Thr	Ala	Met	Val	Asp 270	Thr	Gly	
20	Ser	Ser	Asn 275	Ile	Gln	Gly	Pro	Gly 280	Arg	Val	Ile	Asp	Asn 285	Ile	His	Lys	
25	Leu	Ile 290	Gly	Ala	Thr	Pro	Arg 295	Gly	Ser	Lys	His	Tyr 300	Val	Ser	Cys	Ser	
30	Ala 305	Val	Ser	Ala	Leu	Pro 310	Ser	Val	Val	Phe	Thr 315	Ile	Asn	Gly	Ile	Asn 320	
35	Tyr	Pro	Val	Pro	Ala 325	Arg	Ala	Tyr	Val	Leu 330	Lys	Asp	Phe	Thr	Gly 335	Asn	
40	Cys	Tyr	Thr	Thr 340	Phe	Lys	Glu	Lys	Arg 345	Val	Arg	Arg	Ser	Thr 350	Glu	Phe	
45	Trp	Ile	Leu 355	Gly	Glu	Ala	Phe	Leu 360	Arg	Leu	Tyr	Phe	Ser 365	Val	Phe	Asp	
50	Arg	Gly 370	Asn	Asp	Arg	Ile	Gly 375	Leu	Ala	Arg	Ala	Val 380					
55	<210> 62																
	<211> 380																
	<212> PRT																
	<213> Bos taurus																
	<400> 62																
50	Met 1	Lys	Trp	Val	Val 5	Leu	Leu	Gly	Leu	Val 10	Ala	Phe	Ser	Glu	Cys 15	Ile	
55	Val	Lys	Ile	Pro 20	Leu	Arg	Arg	Val	Lys 25	Thr	Met	Arg	Lys	Thr 30	Leu	Ser	
	Gly	Lys	Asn 35	Met	Leu	Asn	Asn	Phe 40	Leu	Lys	Glu	His	Gly 45	Asn	Arg	Leu	

EP 2 225 274 B1

Ser Lys Ile Ser Phe Arg Gly Ser Asn Leu Thr Thr Leu Pro Leu Arg
50 55 60

5 Asn Ile Glu Asp Leu Met Tyr Val Gly Asn Ile Thr Ile Gly Thr Pro
65 70 75 80

10 Pro Gln Glu Phe Gln Val Val Phe Asp Thr Gly Ser Ser Asp Phe Trp
85 90 95

15 Val Pro Ser Asp Phe Cys Thr Ser Pro Asp Cys Ile Thr His Val Arg
100 105 110

Phe Arg Gln His Gln Ser Ser Thr Phe Arg Pro Thr Asn Lys Thr Phe
115 120 125

20 Ser Ile Thr Tyr Gly Ser Gly Arg Met Arg Gly Val Val Val His Asp
130 135 140

25 Thr Val Arg Ile Gly Asp Leu Val Ser Thr Asp Gln Pro Phe Gly Leu
145 150 155 160

30 Ser Val Ser Glu Tyr Gly Phe Lys Asp Arg Ala Tyr Asp Gly Ile Leu
165 170 175

Gly Leu Asn Tyr Pro Asp Glu Ser Phe Ser Glu Ala Ile Pro Ile Phe
180 185 190

35 Asp Lys Leu Lys Asn Glu Gly Ala Ile Ser Glu Pro Ile Phe Ala Phe
195 200 205

40 Tyr Leu Ser Lys Lys Lys Arg Glu Gly Ser Val Val Met Phe Gly Gly
210 215 220

45 Val Asp His Arg Tyr Tyr Lys Gly Glu Leu Asn Trp Val Pro Leu Ile
225 230 235 240

Glu Glu Gly Asp Trp Ser Val Arg Met Asp Gly Ile Ser Met Lys Thr
245 250 255

50 Lys Val Val Ala Cys Ser Asp Gly Cys Glu Ala Val Val Asp Thr Gly
260 265 270

55 Thr Ser Leu Ile Lys Gly Pro Arg Lys Leu Val Asn Lys Ile Gln Lys
275 280 285

EP 2 225 274 B1

Leu Ile Gly Ala Thr Pro Arg Gly Ser Lys His Tyr Val Tyr Cys Ser
 290 295 300

5 Ala Val Asn Ala Leu Pro Ser Ile Ile Phe Thr Ile Asn Gly Ile Asn
 305 310 315 320

10 Tyr Pro Val Pro Ala Arg Ala Tyr Ile Leu Lys Asp Ser Arg Gly Arg
 325 330 335

15 Cys Tyr Thr Ala Phe Lys Lys Gln Arg Phe Ser Ser Ser Thr Glu Thr
 340 345 350

Trp Leu Leu Gly Asp Ala Phe Leu Arg Val Tyr Phe Ser Val Phe Asp
 355 360 365

20 Arg Gly Asn Gly Arg Ile Gly Leu Ala Gln Ala Val
 370 375 380

25 <210> 63
 <211> 15
 <212> PRT
 <213> Bos taurus

30 <400> 63

Arg Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His Arg Tyr
 1 5 10 15

35 <210> 64
 <211> 10
 <212> PRT
 <213> Bos taurus

40 <400> 64

Arg Leu Tyr Phe Ser Val Phe Asp Arg Gly
 1 5 10

45 <210> 65
 <211> 16
 <212> PRT
 <213> Bos taurus

50 <400> 65

Asn Gln Gly Ala Ile Ser Asp Pro Ile Phe Ala Phe Tyr Leu Ser Lys
 1 5 10 15

55 <210> 66
 <211> 15
 <212> PRT
 <213> Bos taurus

EP 2 225 274 B1

<400> 66

Arg Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His Arg Tyr
 1 5 10 15

5

<210> 67

<211> 11

<212> PRT

<213> Bos taurus

10

<400> 67

Lys Gly Leu Leu Val Tyr Asp Thr Val Arg Ile
 1 5 10

15

<210> 68

<211> 10

<212> PRT

<213> Bos taurus

20

<400> 68

Arg Leu Tyr Phe Ser Val Phe Asp Arg Gly
 1 5 10

25

<210> 69

<211> 18

<212> PRT

<213> Bos taurus

30

<400> 69

Lys Asn Glu Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr Leu Ser
 1 5 10 15

35

Lys Asp

<210> 70

40

<211> 18

<212> PRT

<213> Bos taurus

<400> 70

45

Lys Asp Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His
 1 5 10 15

50

Arg Tyr

<210> 71

<211> 12

<212> PRT

55

<213> Bos taurus

<400> 71

EP 2 225 274 B1

Lys Thr Phe Ser Ile Thr Tyr Gly Ser Gly Arg Ile
1 5 10

5 <210> 72
<211> 19
<212> PRT
<213> Bos taurus

10 <400> 72
Asp Lys Gln Glu Gly Ser Val Val Met Phe Gly Gly Val Asp His Arg
1 5 10 15

15 Tyr Tyr Arg

20 <210> 73
<211> 10
<212> PRT
<213> Bos taurus

<400> 73

25 Arg Leu Tyr Phe Ser Val Phe Asp Arg Gly
1 5 10

30 <210> 74
<211> 18
<212> PRT
<213> Bos taurus

<400> 74

35 Lys Asn Gln Gly Ala Ile Ser Glu Pro Val Phe Ala Phe Tyr Leu Ser
1 5 10 15

40 Lys Asp

Claims

- 45 1. An antibody produced by a hybridoma deposited as ATCC Accession Number PTA-8566, or an antigen-binding fragment thereof.
2. An isolated cell deposited under ATCC Accession Number PTA-8566, or a progeny cell thereof that produces antibody 2D9.
- 50 3. An isolated polynucleotide that encodes an antibody heavy and light chain domain that bind specifically to the pregnancy-associated antigens (PAGs): PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20, and PAG21, where- in the light chain domain is selected from:

55 a polypeptide sequence with at least 97% sequence identity to SEQ ID NO:1 and a polypeptide sequence comprising SEQ ID NO:1; and the heavy chain domain is selected from:

a polypeptide sequence with at least 92% sequence identity to SEQ ID NO:2 and

a polypeptide sequence comprising SEQ ID NO:2.

4. The polynucleotide of claim 3, wherein the polynucleotide encodes the light chain of SEQ ID NO:3 and/or the heavy chain of SEQ ID NO:4.

5. The polynucleotide of claim 3, wherein the polynucleotide comprises SEQ ID NO:5 and/or SEQ ID NO:6.

6. An isolated polypeptide comprising an antibody that binds specifically to the pregnancy-associated antigens (PAGs): PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20, and PAG21, wherein the light chain domain of said antibody is selected from:

a polypeptide sequence with at least 97% sequence identity to SEQ ID NO:1 and a polypeptide sequence comprising SEQ ID NO:1; and
the heavy chain domain of said antibody is selected from:

a polypeptide sequence with at least 92% sequence identity to SEQ ID NO:2; and a polypeptide sequence comprising SEQ ID NO:2.

7. The polypeptide of claim 6, wherein the light chain of the antibody has the polypeptide sequence of SEQ ID NO:3 and the heavy chain of the antibody has the polypeptide of SEQ ID NO:4.

8. A method for detecting pregnancy in a bovine animal comprising:

a) contacting a sample obtained from a bovine animal with an antibody or fragment thereof according to claim 1 or 6; and

b) determining whether the sample contains at least a first pregnancy associated antigen (PAG) that is capable of being bound specifically by the antibody or fragment thereof, wherein the presence of the PAG in the sample is indicative of pregnancy.

9. The method of claim 8, wherein:

i) the antibody or fragment thereof is monoclonal antibody is 2D9;

ii) said determining whether the sample contains at least a first pregnancy associated antigen comprises ELISA or Western blotting;

iii) said determining whether the sample contains at least a first pregnancy associated antigen comprises a sandwich ELISA comprising binding of a PAG to the antibody or fragment thereof fixed to a substrate and a second antibody preparation labeled with an enzyme;

iv) the PAG is selected from PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20, and PAG21; or

v) the PAG is PAG6.

10. A kit comprising:

a) an antibody or fragment thereof according to claim 1 or 6; and

b) a container for the antibody or fragment thereof.

11. The kit of claim 10, wherein:

i) the kit is further defined as containing means for detecting specifically binding between the antibody or fragment thereof and at least a first pregnancy associated antigen (PAG);

ii) the antibody or fragment thereof is attached to a support;

iii) said support is a polystyrene plate, test tube or dipstick;

iv) the kit further comprises a detectable label;

v) the kit further comprises a detectable label that is a fluorescent or chemiluminescent tag;

vi) the kit further comprises a detectable label that is an enzyme; or

vii) the kit further comprises a detectable label that is alkaline phosphatase or horseradish peroxidase.

12. A method of purifying at least a first pregnancy associated antigen (PAG), comprising:

purifying at least a first PAG, relative to a sample obtained from a bovine animal comprising the at least first PAG, based on the affinity of the PAG for the antibody or fragment thereof of claim 1 or 6.

13. The method of claim 12, wherein:

- i) the sample is obtained from day 50 to 250 bovine placenta;
- ii) the sample is obtained from day 61 to 250 bovine placenta; or
- iii) purifying the PAG relative to the sample based on the affinity of the PAG comprises immunoprecipitation, western blot, or immuno-affinity chromatography.

Patentansprüche

1. Antikörper, produziert durch ein Hybridom, das unter der ATCC-Akzessionsnummer PTA-8566 hinterlegt ist, oder antigenbindendes Fragment davon.

2. Isolierte Zelle, die unter der ATCC-Akzessionsnummer PTA-8566 hinterlegt ist, oder Nachkommenzelle davon, die den Antikörper 2D9 produziert.

3. Isoliertes Polynucleotid, das eine schwere und leichte Kettendomäne eines Antikörpers codiert, die spezifisch an die trächtigkeitsassoziierten Antigene (PAGs) PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20 und PAG21 binden, wobei die leichte Kettendomäne ausgewählt ist aus:

einer Polypeptidsequenz mit wenigstens 97% Sequenzidentität mit SEQ ID Nr. 1 und einer Polypeptidsequenz, die SEQ ID Nr. 1 umfasst; und
die schwere Kettendomäne ausgewählt ist aus:

einer Polypeptidsequenz mit wenigstens 92% Sequenzidentität mit SEQ ID Nr. 2 und einer Polypeptidsequenz, die SEQ ID Nr. 2 umfasst.

4. Polynucleotid gemäß Anspruch 3, wobei das Polynucleotid die leichte Kette von SEQ ID Nr. 3 und/oder die schwere Kette von SEQ ID Nr. 4 codiert.

5. Polynucleotid gemäß Anspruch 3, wobei das Polynucleotid SEQ ID Nr. 5 und/oder SEQ ID Nr. 6 umfasst.

6. Isoliertes Polypeptid, das einen Antikörper umfasst, der spezifisch an die trächtigkeitsassoziierten Antigene (PAGs) PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20 und PAG21 bindet, wobei die leichte Kettendomäne des Antikörpers ausgewählt ist aus:

einer Polypeptidsequenz mit wenigstens 97% Sequenzidentität mit SEQ ID Nr. 1 und einer Polypeptidsequenz, die SEQ ID Nr. 1 umfasst; und
die schwere Kettendomäne des Antikörpers ausgewählt ist aus:

einer Polypeptidsequenz mit wenigstens 92% Sequenzidentität mit SEQ ID Nr. 2 und einer Polypeptidsequenz, die SEQ ID Nr. 2 umfasst.

7. Polypeptid gemäß Anspruch 6, wobei die leichte Kette des Antikörpers die Polypeptidsequenz von SEQ ID Nr. 3 aufweist und die schwere Kette des Antikörpers das Polypeptid von SEQ ID Nr. 4 aufweist.

8. Verfahren zum Nachweis einer Trächtigkeit bei einem Rind, umfassend:

- a) In-Kontakt-Bringen einer Probe, die von einem Rind erhalten wurde, mit einem Antikörper oder Fragment davon gemäß Anspruch 1 oder 6; und
- b) Bestimmen, ob die Probe wenigstens ein erstes trächtigkeitsassoziiertes Antigen (PAG) enthält, das von dem Antikörper oder seinem Fragment spezifisch gebunden werden kann, wobei die Anwesenheit des PAG in der Probe auf eine Trächtigkeit hindeutet.

9. Verfahren gemäß Anspruch 8, wobei:

EP 2 225 274 B1

- i) es sich bei dem Antikörper oder seinem Fragment um den monoklonalen Antikörper 2D9 handelt;
- ii) das Bestimmen, ob die Probe wenigstens ein erstes trächtigkeitssassoziiertes Antigen enthält, ELISA oder Western-Blotting umfasst;
- iii) das Bestimmen, ob die Probe wenigstens ein erstes trächtigkeitssassoziiertes Antigen enthält, ein Sandwich-ELISA umfasst, das das Binden eines PAG an den Antikörper oder sein Fragment, der oder das an einem Substrat fixiert ist, und ein zweites Antikörperpräparat, das mit einem Enzym markiert ist, umfasst;
- iv) das PAG aus PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20 und PAG21 ausgewählt ist; oder
- v) es sich bei dem PAG um PAG6 handelt.

5

10

10. Kit, umfassend:

- a) einen Antikörper oder ein Fragment davon gemäß Anspruch 1 oder 6; und
- b) einen Behälter für den Antikörper oder sein Fragment.

15

11. Kit gemäß Anspruch 10, wobei:

- i) der Kit weiterhin dadurch definiert ist, dass er Mittel zum Nachweis einer spezifischen Bindung zwischen dem Antikörper oder seinem Fragment und wenigstens einem ersten trächtigkeitssassoziierten Antigen (PAG) enthält;
- ii) der Antikörper oder sein Fragment an einen Träger gebunden ist;
- iii) der Träger eine Polystyrolplatte, ein Teströhrchen oder ein Teststreifen ist;
- iv) der Kit weiterhin einen nachweisbaren Marker umfasst;
- v) der Kit weiterhin einen nachweisbaren Marker umfasst, bei dem es sich um einen Fluoreszenz- oder Chemilumineszenzmarker handelt;
- vi) der Kit weiterhin einen nachweisbaren Marker umfasst, bei dem es sich um ein Enzym handelt; oder
- vii) der Kit weiterhin einen nachweisbaren Marker umfasst, bei dem es sich um Alkalische Phosphatase oder Meerrettich-Peroxidase handelt.

20

25

12. Verfahren zum Reinigen wenigstens eines ersten trächtigkeitssassoziierten Antigens (PAG), umfassend:

Reinigen wenigstens eines ersten PAG aus einer Probe, die von einem Rind erhalten wurde und das wenigstens erste PAG umfasst, auf der Basis der Affinität des PAG zu dem Antikörper oder seinem Fragment gemäß Anspruch 1 oder 6.

30

13. Verfahren gemäß Anspruch 12, wobei:

- i) die Probe aus 50 bis 250 Tage alter Rinderplacenta erhalten wurde;
- ii) die Probe aus 61 bis 250 Tage alter Rinderplacenta erhalten wurde; oder
- iii) das Reinigen des PAG aus der Probe auf der Basis der Affinität des PAG eine Immunfällung, ein Western-Blotting oder eine Immunaффinitätschromatographie umfasst.

35

40

Revendications

1. Anticorps produit par un hybridome déposé sous le numéro d'accèsion ATCC PTA-8566, ou l'un de ses fragments de liaison de l'antigène.
2. Cellule isolée déposée sous le numéro d'accèsion ATCC PTA-8566, ou l'une de ses cellules descendantes qui produit l'anticorps 2D9.
3. Polynucléotide isolé qui code pour un domaine de chaîne lourde et légère d'anticorps qui se lie spécifiquement aux antigènes associés à la grossesse (PAG) : PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20, et PAG21, où le domaine de chaîne légère est choisi parmi :

45

50

une séquence polypeptidique présentant au moins 97 % d'identité de séquence avec SEQ ID NO : 1 et une séquence polypeptidique comprenant SEQ ID NO : 1 ; et le domaine de chaîne lourde est choisi parmi :

55

une séquence polypeptidique présentant au moins 92 % d'identité de séquence avec SEQ ID NO : 2 et

EP 2 225 274 B1

une séquence polypeptidique comprenant SEQ ID NO : 2.

4. Polynucléotide selon la revendication 3, le polynucléotide codant pour la chaîne légère de SEQ ID NO : 3 et/ou la chaîne lourde de SEQ ID NO : 4.

5. Polynucléotide selon la revendication 3, le polynucléotide comprenant SEQ ID NO : 5 et/ou SEQ ID NO : 6.

6. Polypeptide isolé comprenant un anticorps qui se lie spécifiquement aux antigènes associés à la grossesse (PAG) : PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20, et PAG21, où le domaine de chaîne légère dudit anticorps est choisi parmi :

une séquence polypeptidique présentant au moins 97 % d'identité de séquence avec SEQ ID NO : 1 et une séquence polypeptidique comprenant SEQ ID NO : 1 ; et le domaine de chaîne lourde dudit anticorps est choisi parmi :

une séquence polypeptidique présentant au moins 92 % d'identité de séquence avec SEQ ID NO : 2 et une séquence polypeptidique comprenant SEQ ID NO : 2.

7. Polypeptide selon la revendication 6, où la chaîne légère de l'anticorps a la séquence polypeptidique de SEQ ID NO : 3 et la chaîne lourde de l'anticorps a la séquence polypeptidique de SEQ ID NO : 4.

8. Procédé de détection de la grossesse chez un animal bovin comprenant :

- a) la mise en contact d'un échantillon obtenu à partir d'un animal bovin avec un anticorps ou l'un de ses fragments selon la revendication 1 ou 6 ; et
- b) la détermination si l'échantillon contient au moins un premier antigène associé à la grossesse (PAG) qui peut être lié spécifiquement par l'anticorps ou l'un de ses fragments, où la présence du PAG dans l'échantillon indique une grossesse.

9. Procédé selon la revendication 8, dans lequel :

- i) l'anticorps ou l'un de ses fragments est un anticorps monoclonal 2D9 ;
- ii) ladite détermination si l'échantillon contient au moins un premier antigène associé à la grossesse comprend un test ELISA ou une analyse Western blot ;
- iii) ladite détermination si l'échantillon contient au moins un premier antigène associé à la grossesse comprend un test ELISA de format sandwich comprenant la liaison d'un PAG à l'anticorps ou à l'un de ses fragments fixé à un substrat et une préparation d'un second anticorps marqué avec une enzyme ;
- iv) le PAG est choisi parmi PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20, et PAG21 ; ou
- v) le PAG est le PAG6.

10. Kit comprenant :

- a) un anticorps ou l'un de ses fragments selon la revendication 1 ou 6 ; et
- b) un récipient pour l'anticorps ou l'un de ses fragments.

11. Kit selon la revendication 10, dans lequel :

- i) le kit est en outre défini comme contenant un moyen pour la détection d'une liaison spécifique entre l'anticorps ou l'un de ses fragments et au moins un premier antigène associé à la grossesse (PAG) ;
- ii) l'anticorps ou l'un de ses fragments est fixé à un support ;
- iii) ledit support est une plaque de polystyrène, un tube à essai ou une bandelette réactive ;
- iv) le kit comprend en outre un marqueur détectable ;
- v) le kit comprend en outre un marqueur détectable qui est un marqueur fluorescent ou chimioluminescent ;
- vi) le kit comprend en outre un marqueur détectable qui est une enzyme ; ou
- vii) le kit comprend en outre un marqueur détectable qui est la phosphatase alcaline ou la peroxydase de raifort.

12. Procédé de purification d'au moins un premier antigène associé à la grossesse (PAG), comprenant :

EP 2 225 274 B1

la purification d'au moins un premier PAG, en relation avec un échantillon obtenu à partir d'un animal bovin comprenant l'au moins un premier PAG, basée sur l'affinité du PAG pour l'anticorps ou l'un de ses fragments de la revendication 1 ou 6.

5 **13.** Procédé selon la revendication 12, dans lequel :

i) l'échantillon est obtenu à partir de placenta bovin du jour 50 à 250 ;

ii) l'échantillon est obtenu à partir de placenta bovin du jour 61 à 250 ; ou

10 iii) la purification du PAG en relation avec l'échantillon basée sur l'affinité du PAG comprend une immunoprécipitation, une analyse Western blot ou une chromatographie d'immunoaffinité.

15

20

25

30

35

40

45

50

55

>2D9 Light Chain

CGGTTCCCTGCTCCAGCAGT**G**ATGTTTTGATGACCCAACTCCACTCTCCCTGCCTGTCAGTCTT
GGAGATCAAGCCTCCATTTCTTGCAGATCTAGGCAGAGCATTGTACATAGTAATGGAAACACCTATTTAG
AATGGTTCCCTGCAGAAACCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGG
GGTCCCAGACAGGTT**C**AGTGGCAGTGGATCAGGGACAGATTT**C**ACACTCAAGATCAGCAGAGTGGAGGCT
GAGGATCTGGGAGTTTATTACTGCTTTCAAGGTT**C**ACATGTTCCGCTCAGTTCGGTGCTGGGACCAAGC
TGGAGCTGAAACGGGCTGATGCTGCACCAACTGTATCCATCTTCCACCATCCAGTGAGCAGTTAACATC
TGGAGGTGCCTCAGTCGTGCTTCTTGAACAATTCTACCCCAAGACATCAATGTCAAGTGAAGATT
GATGGCAGTGAACGACAAAATGGCGTCC**T**GAACAGTTGGACTGATCAGGACAGCAAAGACAGCACCTACA
GCATGAGCAGCACCCCTCAGTTGACCAAGGACGAGTATGAACGACATAACAGCTATACCTGTGAGGCCAC
TCACAAGACATCTACTTCACCCATTGTCAAGAGCTTCAACAGGAATGAGTGTTAGAGACAAAGGTCCTGA

FIG. 1

>2D9 Heavy Chain

GCTACAGGTGTCCACTCCCAGGTTTCAGCTGCAGCAGTCTGGAGCTGAGCTGATGAAGCCTGGGGCCTCAG
TGAAGATATCCTGCAAGGCTACTGGCTACATATTCAGTAACTACTGGATGGAGTGGGTAAGCAGAGGCC
TGGACATGGCCTTGAGTGGATTGGAGAGATTTTACCTGGAAGTGATATTACTAACTACAATGAGAAGTTC
AAGGACAAGGCCACATTCACTGCAGATTCATCCTCCAACACGGCCTACATGCAACTCAGCAGCCTGACAT
CTGAGGACTCTGCCGTCTATTACTGTGCAAGAGCTGGGAGTGGTTACTACGGGGTATATTACTATGCTAT
GGACTACTGGGGTCAAGGAACCTCAGTCAOCTCTCCTCAGCCAAAACGACACCCCATCTGTCTATCCA
CTGGCCCTGGATCTGCTGCCCAAATAACTCCATGGTGACCCTGGGATGCCTGGTCAAGGGCTATTTCC
CTGAGCCAGTGACAGTGACCTGGAACCTGGATCCCTGTCCAGCGGTGTGCACACCTTCCCAGCTGTCT
GCAGTCTGACCTCTACACTCTGAGCAGCTCAGTACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTC
ACCTGCAACGTTGCCACCCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCAGGGATTGTGGTT
GTAAGCCTTGCATATGTACAGTCCCAGAAGTATCATCTGTCTTTCATCTTCCCCCAAAGCCAAGGATGT
GCTCACCATTACTCTGACTCCTAAGGTACGTGTGTTGTGGTAGACATCAGCAAGGATGATCCCGAGGTC
CAGTTCAGCTGGTTTGTAGATGATGTGGAGGTGCACACAGCTCAGACGCAACCCCGGAGGAGCAGTTCA
ACAGCACTTTCGGCTCAGTCACTGAACTTCCCATCATGCACCAGGACTGGCTCAATGGCAAGGAGTTCAA
ATGCAGGGTCAACAGTGCAGCTTTCCTGCCCCATCGAGAAAACCATCTCCAAAACCAAAGGCAGACCG
AAGGCTCCACAGGTGTACACCATTCCACCTCCAAGGAGCAGATGGCCAAGGATAAAGTCACTCTGACCT
GCATGATAACAGACTTCTCCCTGAAGACATTACTGTGGAGTGGCAGTGAATGGGCAGCCAGCGGAGAA
CTACAAGAACACTCAGCCCATCATGGACACAGATGGCTTACTTCTGCTACAGCAAGCTCAATGTGCAG
AAGAGCAACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTACATGAGGGCCTGCACAACCACCATA
CTGAGAAGAGCCTCTCCACTCTCCTGGTAAATGATCCCAAAGTCTTGGAGCCCTCTGGTCTACAGGA
CTACTGCAGGTGTCCACTCCCCTCAAACA

FIG. 2

Identification of 2D9 binding PAG antigen LC-MS-MS Analysis

Bos Taurus (NM176617) Pregnancy-associated glycoprotein 6		Pregnancy-associated glycoprotein 6					
Mz	Charge	Mr(calc)	Start	End	Score	Peptide sequence	
853.4334	2	1686.865	147	162	94.87%	IGDLVSTIDQPFGLCLK (SEQ ID NO:7)	
615.2964	2	1210.602	183	193	95.45%	TFSGAFPIFDK (SEQ ID NO:8)	
886.4468	2	1752.872	196	211	98.95%	NEGAISEPVFAFYLSK (SEQ ID NO:9)	
592.9523	3	1757.815	212	227	89.57%	DKQEGSWMFGGVDHR (SEQ ID NO:10)	
767.3938	3	2281.195	266	287	90.78%	ALVDTGTSDIVGSPSTLVNIIWK (SEQ ID NO:11)	
467.2134	2	914.4286	362	368	99%	YFSVFDR (SEQ ID NO:12)	
2D9 Binding PAG antigen							
Mz	Charge	Mr(calc)	Start	End	Score	Peptide sequence	
881.9511	2	1743.886	147	162	99.00%	IGDLVSTIDQPFGLCLK (SEQ ID NO:13)	
615.311	2	1210.602	183	193	99.00%	TFSGAFPIFDK (SEQ ID NO:14)	
886.4475	2	1752.872	196	211	99.00%	NEGAISEPVFAFYLSK (SEQ ID NO:15)	
592.966	3	1757.815	212	227	95.84%	DKQEGSWMFGGVDHR (SEQ ID NO:16)	
767.404	3	2281.195	266	287	97.54%	ALVDTGTSDIVGSPSTLVNIIWK (SEQ ID NO:17)	
467.235	2	914.4286	362	368	84.44%	YFSVFDR (SEQ ID NO:18)	

FIG.3A

Immuno-affinity Purification of PAG with 2D9 monoclonal antibody





FIG.3B



Bands 1 to 7 were cut and subjected to
Trypsin digestion and LC-MS-MS.

FIG.4




FIG.5

β -Study Results
Day 28 PAG and US data

Wisconsin Site

US	PAGs		Percent
	Preg	Open	
Preg	358	11	369 97.0
Open	44	464	508 91.3
	402	475	877

California Site

US	PAGs		Percent
	Preg	Open	
Preg	391	18	409 95.6
Open	41	419	460 91.1
	432	437	869

FIG.6

β -Study Results:
Wisconsin-Synchronized breeding

Characteristic	Early Resynch	Late Resynch	Significance
Number available after 1 st TAI	228	226	
% Preg. to first insemination	46.3	47.9	NS
Days between inseminations	35.1	42.0	P<0.05
Number of inseminations (NI) NI/Conception	2.60	2.65	NS
Days to pregnant (exclude 1 st TAI)	2.29	2.37	NS
Days to pregnant (exclude 1 st TAI)	45.2	58.3	P<0.05
% Preg (exclude 1 st TAI)	46.1	51.4	NS

*Data for 30 cows to resolve

FIG.7

β -Study Results:
California-TAI+Breed to heat

Characteristic	Early Resynch	Late Resynch	Significance
Number available after 1 st TAI	321	335	
% Preg. to first insemination	27.7	28.7	NS
Days between inseminations	28.9	32.3	P<0.05
Number of inseminations (NI) NI/Conception	2.86	3.05	P<0.05
	2.49	2.77	P<0.05
Days to pregnant (exclude 1 st TAI)	37.9	48.0	P<0.05
% Preg (exclude 1 st TAI)	36.6	36.2	NS

*Data for 42 cows to resolve

FIG.8





FIG. 9

Bovine Pregnancy Diagnosis with Color Test



Blue - Pregnant
Clear - Non-pregnant (Open)

FIG.10




FIG.11A




FIG.11B

PAG color assay
Fresh Plasma Samples





FIG. 12




FIG.13

Color Test: Field testing

Total number of samples tested: 54
 Days 33 to 34 after breeding

	Pregnant	Open	Recheck
PAGs	15	37	2
US	14	40	
Agreement	14	36	

Test was read by 3 people
 1 false-positive in tube test

FIG.14




FIG.15

Btau 029432 PAG1I...I	10I...I	20I...I	30I...I	40I...I	50I...I	60
Btau 046492 PAG4	MKWLVLGLV	AFSBCIVKIP	LRRLKTMRN	VSGKNMLN	NF	LKEHAYSLSQ	ISFRGSNLTT					
Btau 046494 PAG6V...V	TKT	LR...RI							
Btau A5PJW4 PAG6V...V	A	IT...TIR.P.H					
Btau A4PV16 PAG9V...V	A	IT...TIR.P.H					
Btau 046497 PAG9QV...QV	KT	LK...KP.R.P.R.I					
Btau 09TTV8 PAG16QV...QV	KT	LK...KP.R.P.R.I					
Btau 09TTV7 PAG17V...V	KT	LT...TP.R.P.R.H					
Btau A7MBA4 PAG17W...WKT	LT...TT...TSI					
Btau Q9TTV5 PAG19W...WKT	LT...TT...TSI					
Btau Q9TTV4 PAG20V...V	KA	LR...RR...RSS					
Btau Q9TTV3 PAG21V...V	FKT	LP.K.P.K.K					
V...VKT	LG.NR.G.NR.KK					
I...I	70I...I	80I...I	90I...I	100I...I	110I...I	120
Btau 029432 PAG1	HPLRNKDLV	YMGNITIGTP	PQBFQVFD	T	ASSDLWVPSD	FCTSPACSTH	VFRHLQSS					
Btau 046492 PAG4R.FFVIG.E.IN.ST.K.D.					
Btau 046494 PAG6	PLRNIRDLFY	VGNITIGTP	QBFQVIFDTG	S.DLWASIF	CNS.SCAAHV	RFRH.QS	TF					
Btau A5PJW4 PAG6	PLRNIRDLFY	VGNITIGTP	QBFQVIFDTG	S.DLWASIF	CNS.SCAAHV	RFRH.QS	TF					
Btau A4PV16 PAG9MN..VGF	CTMPACSAPV	WFRQLQS	TF					
Btau 046497 PAG9MN..VGF	CTMPACSAPV	WFRQLQS	TF					
Btau 09TTV8 PAG16	LR.ML	VGFF						
Btau 09TTV7 PAG17M.ML	VGV	Q.L.A.K	M.I.H					
Btau A7MBA4 PAG17M.ML	VGV	Q.L.A.K	M.I.Y					
Btau Q9TTV5 PAG19LAFLGGKK					
Btau Q9TTV4 PAG20	LW.IF	I.TI	I.N.STR					
Btau Q9TTV3 PAG21	LB.M	VG	FD.IQ.H					

FIG.16

Btau 029432 PAG1I...I	130	140	150	160	170	180
Btau 046492 PAG4	FRLTNKTFRI	TYGSRMKGV	WHDTVRI	GN LVST	QDPFGL	SIEEYGF	EGR IYD
Btau 046494 PAG6	...SRR...SIBALDQ...	CL...S...	M RFS.
Btau A5PJW4 PAG6	RPTNKTFRIT	YGSRMKGV	.HDTVRI	IGDL V	STDPQF	GLC LK	DGSGFK
Btau A4PV16 PAG9	RPTNKTFRIT	YGSRMKGV	.HDTVRI	IGDL V	STDPQF	GLC LK	DGSGFK
Btau 046497 PAG9	QPTNKTFIT	YGSGSMKGL	AYDTRIG	DL V	STDPQF	GLS VV	.YGLEGR
Btau 09TTV8 PAG16	QPTNKTFIT	YGSGSMKGL	AYDTRIG	DL V	STDPQF	GLS VV	.YGLEGR
Btau 09TTV7 PAG17	..P.T.....	I.....ADCI	LA.V..D	.I PF
Btau A7MBA4 PAG17	..H.Q.V.N.	K.NT.....	L.Y.....	DCI	LA.V..D	.I PF
Btau Q9TTV5 PAG19	..H.Q.V.N.	K.NT.....	L.Y.....	DCI	LA.V..D	.I PF
Btau Q9TTV4 PAG20S.I...	A.....DS.	MA...L	.HI PF	..I.....
Btau Q9TTV3 PAG21G.DDVA	RF
	..P.....SR..DVSKD	.A..I.....
I...I	190	200	210	220	230	240
Btau 029432 PAG1	PNISFSGAIP	IFDKLKNORA	ISBPVFA	FYL SK	DEREGSV	MFGGV	DHRY
Btau 046492 PAG4	T...P.....	Y...BG
Btau 046494 PAG6	NKTFSGAFPI	FDKLKNEGAI	SBPVFA	FYLS	KDKQEGSV	M FG	.VDHRY
Btau A5PJW4 PAG6	NKTFSGAFPI	FDKLKNEGAI	SBPVFA	FYLS	KDKQEGSV	M FG	.VDHRY
Btau A4PV16 PAG9	NISFSGAIP	FDKLKNQAI	SBPVFA	FYLS	KDKQEGSV	M FG	.VDHQY
Btau 046497 PAG9	NISFSGAIP	FDKLKNQAI	SBPVFA	FYLS	KDKQEGSV	M FG	.VDHQY
Btau 09TTV8 PAG16	..L.C.....G.	..D.I
Btau 09TTV7 PAG17	..M.....	..N...BG
Btau A7MBA4 PAG17	..M.....	..N...BG
Btau Q9TTV5 PAG19	..V.S.....G.
Btau Q9TTV4 PAG20K...BG
Btau Q9TTV3 PAG21	..DE...E...BGI

FIG.16-1

Btau 029432 PAG1I...I	250I...I	260I...I	270I...I	280I...I	290I...I	300
Btau 046492 PAG4	QAGDWSVHMD	RISIBRKIIA	CSDGCKALVD	TGTSDIVGPR	RLVNNIHRLI	GAIPRGSEHY	K.....	...MK..V..	..G.....	..S.....	..T.....	..T.Q.....
Btau 046494 PAG6	VGDWVHMDR	TTMKRKV.AC	SDGCKALVDT	GTSDIVGPST	LVN.IWKLIR	ARPLGPQYFV	VGDWVHMDR	ITMKRKV.AC	SDGCKALVDT	GTSDIVGPST	LVN.IWKLIR	ARPLGPQYFV
Btau A5PJW4 PAG6	AGEWRVHMDR	ISMKRTV.AC	SDGCEALVHT	GTSHIEGPG.	LVN.IHRLIR	TRPFDSKHYY	AGEWRVHMDR	ISMKRTV.AC	SDGCEALVHT	GTSHIEGPG.	LVN.IHRLIR	TRPFDSKHYY
Btau A4PV16 PAG9	AGEWRVHMDR	ISMKRTV.AC	SDGCEALVHT	GTSHIEGPG.	LVN.IHRLIR	TRPFDSKHYY	R....I..V.	..TMK.BV..A....L.Q..G	.VID...K..	..T....K..
Btau 046497 PAG9	...G.T..V.	...MK.....	..G.E.....	...AL.K...QK..	.TT....K..	...G.T..V.	...MK.....	..G.E.....	...AL.K...QK..	.TT....K..
Btau 09TTV8 PAG16	...N.II....	S.....V..	..G..V.F..	I..AF.E..K	P..D.MOK..	R.K.WR.K..	...N.II....	S.....V..	..G..V.F..	I..AF.E..K	P..D.MOK..	R.K.WR.K..
Btau 09TTV7 PAG17												
Btau A7MBA4 PAG17												
Btau Q9TTV5 PAG19												

FIG.16-2




FIG.17

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6869770 B [0008] [0126]
- US 20050100975 A [0008] [0126]
- US 4554101 A [0037]
- US 4376110 A [0048] [0126]
- US 4699880 A [0050] [0126]
- US 3646346 A [0056] [0126]
- WO 9816832 A [0056] [0126]
- US 3817837 A [0058] [0126]
- US 3850752 A [0058] [0126]
- US 3939350 A [0058] [0126]
- US 3996345 A [0058] [0126]
- US 4277437 A [0058] [0126]
- US 4275149 A [0058] [0126]
- US 4366241 A [0058] [0126]
- US 5721105 A [0058] [0126]
- US 2003508381 A [0059] [0126]
- US 4367110 A [0063] [0126]
- US 4452901 A [0063] [0126]
- US 4668621 A [0070] [0126]
- WO 61013603 A [0127]

Non-patent literature cited in the description

- *Computational Molecular Biology*, 1988 [0028]
- *Biocomputing: Informatics and Genome Projects*, 1993 [0028]
- *Computer Analysis of Sequence Data*, 1994 [0028]
- *Sequence Analysis in Molecular Biology*, 1987 [0028]
- *Sequence Analysis Primer*, 1991 [0028]
- *Antibodies: A Laboratory Manual*. Cold Spring Harbor Laboratory, 1988 [0042]
- **ABBONDANZO et al.** *Breast Cancer Res. Treat.*, 1990, vol. 16 (151), 182 [0126]
- **ALLRED et al.** *Breast Cancer Res. Treat.*, 1990, vol. 16 (149), 182 [0126]
- **ATKINSON et al.** *J. Biol. Chem.*, 1993, vol. 268 (35), 26679-26685 [0126]
- **AUSUBEL et al.** *Current Protocols in Molecular Biology*. John, Wiley & Sons, Inc, 1994 [0126]
- **BEAL et al.** *J. Anim. Sci.*, 1992, vol. 70, 924-929 [0126]
- *Biocomputing: Informatics and Genome Projects*. Academic Press, 1993 [0126]
- **BOULIANNE et al.** *Nature*, 1984, vol. 312, 643-646 [0126]
- **BROWN et al.** *Breast Cancer Res. Treat.*, 1990, vol. 16 (191), 192 [0126]
- **BUTLER et al.** *Biol. Reprod.*, 1982, vol. 26, 925-933 [0126]
- **CABILLY et al.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 91, 3273-3277 [0126]
- **CAMERON ; MALMO.** *Austr. Vet. J.*, 1993, vol. 70, 109-111 [0126]
- **CAPALDI et al.** *Biochem. Biophys. Res. Comm.*, 1977, vol. 76, 425 [0126]
- **CHARDES et al.** *FEBS Lett.*, 1999, vol. 452 (3), 386-394 [0126]
- **COLLIGAN et al.** *Current Protocols in Immunology*. Greene Publ. Assoc. Wiley Interscien, 1993 [0126]
- *Computational Molecular Biology*. Oxford University Press, 1988 [0126]
- *Computer Analysis of Sequence Data*. Humana Press, 1994 [0126]
- **CUMBER et al.** *J. Immunology*, 1992, vol. 149B, 120-126 [0126]
- **ENGVALL.** *Lancet*, 1976, vol. 2 (8000), 1410 [0126]
- **ENGVALL.** *Med Biol.*, 1977, vol. 55 (4), 193-200 [0126]
- **ENGVALL.** *Methods Enzymol.*, 1980, vol. 70 (A), 419-39 [0126]
- **FELSENSTEIN.** *Cladistics*, 1989, vol. 5, 164-166 [0126]
- **GREEN et al.** *Theriogenology*, 2005, vol. 63 (5), 1481-1503 [0126]
- **GREEN et al.** *Biol Reprod*, 2000, vol. 62, 1624-1631 [0126]
- **GREEN et al.** *Biol Reprod*, 1999, vol. 60, 1069-1077 [0126]
- **GRIPENBERG et al.** *Scand J Immunol*, 1978, vol. 7 (2), 151-7 [0126]
- **GURUPRASAD et al.** *Protein Eng*, 1996, vol. 9, 849-856 [0126]
- **HALL.** *Nucl. Acids. Symp. Ser.*, 1999, vol. 41, 95-98 [0126]
- **HARLOW ; LANE.** *Antibodies, a Laboratory, Manual*. Cold Spring Harbor Laboratory, 1988, 139-281 [0126]
- **HATZIDAKIS et al.** *J. Reprod Fertil.*, 1993, vol. 98, 235-240 [0126]
- **HIGGINS ; SHARP.** *CABIOS*, 1989, vol. 5, 151-153 [0126]

EP 2 225 274 B1

- **HOLDSWORTH et al.** *J. Endocrin.*, 1982, vol. 95, 7-12 [0126]
- **HUGHES et al.** *Mol Biol Evol.*, 2003, vol. 20, 1940-1945 [0126]
- **HUMBLOT et al.** *Theriogenol.*, 1988, vol. 30, 257-268 [0126]
- **KIRACOFÉ et al.** *J. Anim. Sci.*, 1993, vol. 71, 2199-2205 [0126]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495-497 [0126]
- **LEIBIGER et al.** *Biochem J.*, 1999, vol. 338, 529-538 [0126]
- **LIU et al.** *Cell Mol. Biol.*, 2003, vol. 49 (2), 209-216 [0126]
- **MAKLER et al.** *Transfusion*, 1981, vol. 21 (3), 303-312 [0126]
- **MARKUSFELD et al.** *Br. Vet. J.*, 1990, vol. 146, 504-508 [0126]
- **MIALON et al.** *Reprod Nutr. Dev.*, 1993, vol. 33, 269-282 [0126]
- **MIALON et al.** *Reprod. Nutr. Dev.*, 1994, vol. 34, 65-72 [0126]
- **MO et al.** *Eur. J. Immunol.*, 1993, vol. 23, 2503-2510 [0126]
- **NAKAMURA et al.** *Handbook of Experimental Immunology.* Blackwell Scientific Publ, 1987, vol. 1, 27 [0126]
- **NEUBERGER et al.** *Nature*, 1985, vol. 314, 268-270 [0126]
- **OLTENACU et al.** *J. Dairy Sci.*, 1990, vol. 73, 2826-2831 [0126]
- **PACK et al.** *Biochem.*, 1992, vol. 31, 1579-1584 [0126]
- **SARNGADHARAN et al.** *Princess Takamatsu Symp.*, 1984, vol. 15, 301-8 [0126]
- **SASSER et al.** *Biol. Reprod.*, 1986, vol. 35, 936-942 [0126]
- *Sequence Analysis in Molecular Biology.* Academic Press, 1987 [0126]
- *Sequence Analysis Primer.* Stockton Press, 1991 [0126]
- **SZAFRANSKA et al.** *Biol. Reprod.*, 1995, vol. 53, 21-28 [0126]
- **WAGNER et al.** *Science*, 1993, vol. 260 (5113), 1510-1513 [0126]
- **WARNICK et al.** *Theriogenol.*, 1995, vol. 44, 811-825 [0126]
- **XIE et al.** *Biol. Reprod.*, 1994, vol. 51, 1145-1153 [0126]
- **XIE et al.** *Biol. Reprod.*, 1996, vol. 54, 122-129 [0126]
- **XIE et al.** *Biol. Reprod.*, 1997, vol. 57, 1384-1393 [0126]
- **XIE et al.** *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 10247-10251 [0126]
- **XIE et al.** *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 12809-12816 [0126]
- **ZOLI et al.** *Biol. Reprod.*, 1991, vol. 45, 1-10 [0126]
- **ZOLI et al.** *Biol. Reprod.*, 1992, vol. 46, 83-92 [0126]

专利名称(译)	用于早期妊娠诊断的组合物和方法		
公开(公告)号	EP2225274B1	公开(公告)日	2017-02-15
申请号	EP2008860515	申请日	2008-12-12
[标]申请(专利权)人(译)	密苏里大学		
申请(专利权)人(译)	MONSANTO科技有限责任公司 密苏里大学的策展人		
当前申请(专利权)人(译)	MONSANTO科技有限责任公司 密苏里大学的策展人		
[标]发明人	MATHIALAGAN NAGAPPAN ROBERTS R MICHAEL MCGRATH MICHAEL F GREEN JONATHAN		
发明人	MATHIALAGAN, NAGAPPAN ROBERTS, R., MICHAEL MCGRATH, MICHAEL, F. GREEN, JONATHAN		
IPC分类号	C07K16/18 G01N33/53 G01N33/68		
CPC分类号	C07K16/18 G01N33/6803 G01N2333/471		
优先权	61/013603 2007-12-13 US		
其他公开文献	EP2225274A1		
外部链接	Espacenet		

摘要(译)

公开了用于检测动物妊娠的抗体和方法。在某些方面，使用的抗体免疫结合至少两种选自PAG4，PAG6，PAG9，PAG16，PAG17，PAG19，PAG20和PAG21的PAG。还提供了编码抗体的核酸，试剂盒，使用方法和其他抗体相关组合物也是如此。

Table 1. Summary of peptide sequence results

Protein Band No.: Present in Bands 3, 5, 6 & 7						
Bos Taurus (gi28603710) Pregnancy-associated glycoprotein 4						
Mz	Charge	Mr(calc)	Start	End	Score	Peptide sequence
494.7897	2	969.5647	323	331	97.72%	VPGQAYILK (SEQ ID NO:19)
523.7799	2	1027.5127	362	369	99.00%	LYFSVFDR (SEQ ID NO:20)
544.7657	2	1069.5193	127	136	98.95%	TFSITYGSGR (SEQ ID NO:21)
608.8262	2	1197.6216	232	241	94.10%	GELNWIPLMK (SEQ ID NO:22)
671.695	3	1994.0513	195	212	99.00%	LKNEGAISEPVFAFYLSK (SEQ ID NO:23)
820.4574	3	2440.2678	172	194	87.95%	FDGVLGLSYTNISPSGAIPIFYK (SEQ ID NO:24)